

Identification of 5-HT_{2A} Receptor Signaling Pathways Responsible for Psychedelic Potential

Jason Wallach^{1*}, Andrew B. Cao⁶, Maggie M. Calkins⁶, Andrew J. Heim², Janelle K. Lanham⁶, Emma M. Bonniwell⁶, Joseph J. Hennessey⁶, Hailey A. Bock⁶, Emilie I. Anderson⁶, Alexander M. Sherwood³, Hamilton Morris¹, Robbin de Klein⁵, Adam K. Klein^{4^}, Bruna Cuccurazzu⁴, James Gamrat¹, Tilka Fannana¹, Randy Zauhar², Adam L. Halberstadt^{4,5*}, John D. McCorvy^{6*}

¹Department of Pharmaceutical Sciences, Saint Joseph's University, Philadelphia, Pennsylvania 19104, United States

²Department of Chemistry, Saint Joseph's University, Philadelphia, Pennsylvania 19104, United States

³Usona Institute, Madison, Wisconsin, 53711, United States

⁴Department of Psychiatry, University of California San Diego, La Jolla, California 92093, United States

⁵Research Service, VA San Diego Healthcare System, San Diego, California 92161, United States

⁶Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

[^] Present address: Gilgamesh Pharmaceuticals, New York, NY 10003

*Corresponding authors:

Jason Wallach: jwallach@sju.edu

Adam L. Halberstadt: ahalberstadt@health.ucsd.edu

John D. McCorvy: jmccorvy@mcw.edu

Summary

Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT_{2A} receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT_{2A}-Gq/11 and β -arrestin2 signaling, making their respective roles unclear. To elucidate this, we developed a series of 5-HT_{2A}-selective ligands with varying Gq efficacies, including β -arrestin-biased ligands. We show that 5-HT_{2A}-Gq but not 5-HT_{2A}- β -arrestin2 efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT_{2A} partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT_{2A}-Gq efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT_{2A} agonists. We also demonstrate that β -arrestin-biased 5-HT_{2A} receptor agonists induce receptor downregulation and tachyphylaxis, and have an anti-psychotic-like behavioral profile. Overall, 5-HT_{2A} receptor signaling can be fine-tuned to generate ligands with properties distinct from classical psychedelics.

Introduction

Classical (serotonergic) psychedelics have undergone a resurgence of interest due to their potential to produce rapid and sustained therapeutic effects^{1,2}. The therapeutic properties of psychedelics are being explored both preclinically and clinically, but studies have focused on a limited number of compounds^{3,4}. The therapeutic use of psychedelics may be limited by their hallucinogenic effects, which can cause confusion and anxiety in some patients, necessitating close clinical supervision. Recent preclinical work, however, suggests it may be possible to disentangle the psychedelic and therapeutic properties^{5,6}. Nevertheless, fundamental questions exist regarding which receptors and signaling pathways mediate the effects of psychedelics, limiting the rational design of new molecules.

Serotonergic psychedelics are derived from multiple chemical scaffolds (e.g., tryptamines, phenethylamines, and lysergamides), all which activate the 5-HT_{2A} receptor (5-HT_{2A}R), a G protein-coupled receptor (GPCR). 5-HT_{2A}Rs appear to primarily mediate psychedelic experiences as evident with studies with the 5-HT_{2A}R antagonist ketanserin, which attenuates subjective effects of psilocybin and LSD in humans^{7,8}. Responses to psychedelics has also been studied in preclinical behavioral models, including the head-twitch response (HTR), which is a 5-HT_{2A}R-mediated involuntary head movement in mice that predicts human psychedelic activity⁹. Multiple receptors, however, appear to contribute to the behavioral effects of existing psychedelics, including psilocybin¹⁰ and LSD¹¹, which adds to their complicated psychopharmacology.

Ligands targeting GPCRs can stabilize certain receptor conformations that energetically favor coupling to subsets of transducer proteins^{12,13}. Ligand-dependent bias has important implications for drug development and clinical pharmacology^{14,15}. For example, the G protein-biased μ -opioid receptor (MOR) agonist oliceridine reportedly has a correspondingly improved tolerability profile¹⁶, although alternative explanations exist¹⁷. As existing psychedelics activate both Gq and β -arrestin2 via 5-HT_{2A}R^{18,19}, the role these pathways play in the effects of psychedelics is unclear. Although putative non-psychedelic 5-HT_{2A}R agonists exist^{5,6}, an adequate explanation for their lack of psychedelic action does not exist. A clear and defined pharmacological signaling mechanism explaining why certain 5-HT_{2A}R agonists lack psychedelic effects is thus needed.

Herein, we utilized structure-inspired design to develop 5-HT_{2A}R-selective ligands acting as biased agonists and leveraged these compounds to develop a mechanistic and molecular explanation of biased 5-HT_{2A}R signaling. Furthermore, these compounds were used to probe the relationship between 5-HT_{2A}R-Gq

versus 5-HT_{2A}R-β-arrestin activity and psychedelic potential *in vivo*. Our goal was to identify the 5-HT_{2A}R-coupled signaling pathways mediating psychedelic activity for the design of next-generation 5-HT_{2A}R agonists.

Results

Psychedelics exhibit similar Gq and β -arrestin2 activity at 5-HT_{2A}R

To investigate the 5-HT_{2A}R signaling profiles of classical psychedelics, we used bioluminescence resonance energy transfer approaches (BRET, Fig. 1A,B, Supplementary Table 1), which provide a proximity measure of intracellular transducer engagement. BRET is used extensively to quantify GPCR biased agonism and has the advantage of not being susceptible to second messenger amplification or receptor reserve issues obfuscating GPCR signaling preference determinations²⁰. BRET has been used to measure 5-HT_{2A}R- β -arrestin2 and 5-HT_{2A}R-Gq activity directly¹¹, and to confirm 5-HT_{2A}R G protein coupling preferences¹⁸. In our assay platform, 5-HT_{2A}R strongly couples to Gq/11 and β -arrestin2 over all other G protein subtypes and β -arrestin1 (Fig. 1C).

Next, we tested classical psychedelics from multiple chemical classes and examined their effects on Gq and β -arrestin2 (Fig. 1D-K). Kinetic issues can confound studies of ligand-directed bias²¹, and slow ligand kinetics can delay full receptor occupancy, as in the case for LSD at 5-HT_{2A}R¹⁹. Therefore, we thoroughly assessed Gq and β -arrestin2 activities at various time points at 37°C to ensure full receptor occupancy and confirm that transducer signaling preferences do not substantially change when compared at the same time point. Our results show that psychedelics exhibit dynamic, time-dependent profiles of Gq and β -arrestin activity that in some cases exceeds the activity of 5-HT (i.e., superagonism) at longer time points (e.g., 300 minutes, Supplementary Fig. 1A-H), which is not surprising given the dynamic temporal nature of GPCR signaling²². For all tested psychedelics, however, effects on Gq and β -arrestin were strikingly similar at equivalent time points and closely mirrored the pathway-balanced endogenous ligand 5-HT (Heat map, Fig. 1L), indicating no strong preferences for one of the transducers. Psilocin, DMT and 2C-I showed slightly less β -arrestin2 efficacy compared to Gq activity, but the difference was not substantial when both transducers were compared at each respective time point (Supplementary Fig. 1B,C,E). Importantly, all tested psychedelics lacked a clear preference for Gq or β -arrestin2, demonstrating these compounds are not substantially biased for either transducer.

Rational design of a 5-HT_{2A}-selective agonist template

To engineer a series of biased agonists for interrogating the 5-HT_{2A}R-coupled signaling pathways responsible for psychedelic potential, a scaffold exhibiting some degree of selectivity for 5-HT_{2A}R over other 5-HT receptors

is required. Most psychedelics are not selective for 5-HT_{2A}R, exhibiting complex polypharmacology¹¹. 5-HT_{2A}R shares considerable homology with 5-HT_{2B}R and 5-HT_{2C}R, making it challenging to develop selective 5-HT_{2A}R agonists. To date, few 5-HT_{2A}R-selective agonists have been discovered, but the *N*-benzyl-phenethylamines 25CN-NBOH²³ and DMBMPP²⁴ are purported examples. Importantly, recently discovered “non-psychedelic” 5-HT_{2A}R agonists show little selectivity for 5-HT_{2A}R^{5,6}, complicating attempts to interpret their psychopharmacology.

To develop selective 5-HT_{2A}R biased ligands, we focused on the phenethylamine scaffold, which tends to have high selectivity for 5-HT₂ subtypes. 25N or 2C-N (1) was selected as the core phenethylamine based on previous reports of potential 5-HT_{2A}R biased agonism^{25,26}. We confirmed 25N (1) is a high-affinity, potent 5-HT₂ agonist with weak selectivity for 5-HT_{2A}R and 5-HT_{2C}R over 5-HT_{2B}R (Fig. 2A, Supplementary Table 8). Because *N*-benzylation can increase affinity and potency of phenethylamines at 5-HT_{2A}R²⁷, we converted 25N (1) to 25N-NB (2) (see Supplement for all synthetic schemes), which reduced 5-HT_{2B}R efficacy substantially (E_{MAX} = 32% of 5-HT, Fig. 2A). Unfortunately, 25N-NB (2) retained potent 5-HT_{2C}R activity (EC₅₀ = 8.3 nM), resulting in a weakly (4-fold) 5-HT_{2A}R-selective ligand.

To optimize 5-HT_{2A}R affinity and selectivity, we synthesized a series of 25N-NB analogs designed to modify the electrostatic properties of the *N*-benzyl ring system (Supplementary Fig. 2; Supplementary Table 2). The increased 5-HT_{2A}R affinity of *N*-benzyl-phenethylamines is thought to result in part from hydrogen bonding between the *N*-benzyl 2-position and residues in 5-HT_{2A}R²⁸, but we developed an alternate hypothesis that ring-electrostatics (i.e. the effect of increasing π -electron density in portions of the *N*-benzyl-ring, quantified as ring-substituents with negative Hammett constants relative to C₅) drives 5-HT_{2A}R affinity (Fig. 2B, Supplementary Fig. 3; Supplementary Table 3). Using the 25N series, we found that estimates of increasing electron density around the *N*-benzyl C₅ position (para to the 2'-position) increase 5-HT_{2A}R binding affinity and agonist potency (Supplementary Fig. 3; Supplementary Tables 3-8). To confirm the importance of this ring-region, we tested the effect of adding a methoxy group to the C₅ position of 25N-NBOMe (4), which this analog 25N-NB-2,5-DiMeO (20) reduced affinity 400-fold, suggesting steric clash and/or altered electronics disrupted optimal electrostatic interaction (Supplementary Fig. 3J). The electrostatic-relationship was supported by correlations with additional potency estimates, experimental NMR chemical shifts, and *in silico* Hirshfeld surface analyses (Supplementary Fig. 3A-I, K-P, Supplementary Table 4-6). This resulted in the discovery of

several high-affinity 5-HT_{2A}R agonists within the *N*-benzyl-phenethylamine class of psychedelics

(Supplementary Table 8).

We then examined the effect of *N*-benzyl 2-position substitutions on 5-HT_{2A}R selectivity for the 25N series. In the 2-halogen series, a larger/bulkier 2-bromo or 2-iodo atom on the *N*-benzyl ring reduced 5-HT_{2C}R and 5-HT_{2B}R activity substantially but retained potent 5-HT_{2A}R activity, resulting in increased 5-HT_{2A}R selectivity (Fig. 2C, Supplementary Fig. 4A). We compared 25N-NBI (10), the most selective 5-HT_{2A}R agonist from this series, to the purported 5-HT_{2A}R-selective agonist 25CN-NBOH²⁹ and determined 25N-NBI (10) showed 23-fold selectivity for 5-HT_{2A}R over 5-HT_{2C}R, whereas 25CN-NBOH shows only 7-fold selectivity (Fig. 2D). We confirmed the superior 5-HT_{2A}R selectivity of 25N-NBI (10) using an orthogonal assay measuring Gq-mediated calcium flux (Supplementary Fig. 4B; Supplementary Table 7), confirming in two functional assays that 25N-NBI (10) has greater 5-HT_{2A}R selectivity than 25CN-NBOH. 25N-NBI (10) also showed selectivity for 5-HT_{2A}R over 5-HT_{2B}R and 5-HT_{2C}R in competitive binding studies (Supplementary Table 8). Furthermore, when tested at >40 other 5-HT receptors and off-targets, 25N-NBI (10) exhibited weak micromolar affinity for all targets screened (Supplementary Table 9). Competitive radioligand binding studies showed high selectivity for 5-HT₂ subtypes across the series (Supplementary Table 8-10). Finally, 25N-NBI (10) induced the HTR in mice (ED₅₀ = 10.9 μmol/kg), confirming selective 5-HT_{2A}R agonists possess psychedelic potential (Supplementary Fig. 4C).

Although a 2-iodo *N*-benzyl substitution yielded a 5-HT_{2A}R-selective agonist with psychedelic potential, 25N-NBI (10) did not show a preference for either 5-HT_{2A}R-Gq or 5-HT_{2A}R-β-arrestin2 activity (Supplementary Fig. 4D). Therefore, we focused on another 25N analog, 25N-NB-2-OH-3-Me (18; Fig. S2A), which was rationally designed to maximize C₅ electron density (Supplementary Fig. 3A, Supplementary Tables 3,4) and confirmed to have the highest 5-HT_{2A}R affinity in the 25N series (Fig. 2B,E). 25N-NB-2-OH-3-Me (18) showed a selective reduction in 5-HT_{2A}R-Gq efficacy but not 5-HT_{2A}R-β-arrestin2 efficacy compared to 25N-NBOH (3) (Fig. 2E), which lacks 3-methyl substitution, providing a critical clue that steric effects in the 3-position influence 5-HT_{2A}R biased-agonist activity.

To gain additional insights into the binding mode of the 25N series, we docked 25N-NBI (10), 25N-NB-2-OH-3-Me (18), and other analogs into the Gq-bound 5-HT_{2A}R cryo-EM structure (6WHA)¹⁸ using induced fit docking (IFD) (Fig. 2F; Supplementary Fig. 5). Consistent with other studies^{18,27}, the *N*-benzyl groups formed

an edge-to-face π - π stacking interaction with F339^{6.51} and F340^{6.52}, known drivers of high 5-HT_{2A}R affinity^{27,30} (Fig. 2D and Supplementary Table 20). We validated this docking pose and the 5-HT_{2A}R model using a series of binding pocket mutants. Examination of mutants in transmembrane 6 (TM6), extracellular loop 2 (EL2), TM3, and TM7 indicate the 25N analog binding poses are consistent with the 25CN-NBOH-bound cryo-EM structure. Specifically, mutants of key aromatic anchor residues, F339^{6.51}L and F340^{6.52}L, showed complete loss of 25N-NBI (10) Gq activity (Supplementary Fig. 4E), suggesting the *N*-benzyl moiety is positioned near TM6. In summary, we found that 5-HT_{2A}R affinity, selectivity, and potentially biased agonism can be modulated in the 25N series, and that additional bulk in the 2- and 3-positions of the *N*-benzyl ring may drive 5-HT_{2A}R selectivity and ligand bias, respectively (Fig. 2E-G).

Structure-based design of β -arrestin-biased 5-HT_{2A} agonists

Based on the promising results obtained with the initial 25N series that led to increased 5-HT_{2A}R selectivity, we explored whether it is possible to reduce Gq signaling further by replacing the *N*-benzyl ring with bulkier bi-aryl ring systems such as *N*-naphthyl (25N-N1-Nap (16)) and *N*-biphenyl (25N-NBPh (17)). Steric interactions within GPCR binding pockets are an important driver of agonist, antagonist, and biased-agonist conformational states, especially when they involve residues in the extended binding pocket encompassing TM6 and TM7^{12,31}. Strikingly, 25N-N1-N (16) and 25N-NBPh (17) showed a substantial reduction in 5-HT_{2A}R-Gq efficacy yet preserved 5-HT_{2A}R- β -arrestin: efficacy, thus exhibiting β -arrestin-biased agonism at 5-HT_{2A}R compared to the balanced agonist 25N-NBOMe (4) (Fig. 3A; Supplementary Table 13). We further explored the SAR by synthesizing *N*-benzyl analogs containing ortho and 3-substituents and this also results in β -arrestin bias (Supplementary Fig. 6A). Similar to our findings with 25N-NBI (10), the bulky analogs 25N-N1-Nap (16) and 25N-NBPh (17) showed weaker Gq activity at 5-HT_{2B}R and 5-HT_{2C}R, retaining degrees of 5-HT_{2A}R selectivity (Supplementary Fig. 6B; Supplementary Tables 13 and 14). Binding affinities confirmed these compounds exhibit weak affinities for other 5-HT receptors and off-targets (Supplementary Table 8-10). To test whether the β -arrestin bias was specific for 5-HT_{2A}R, we measured β -arrestin2 activity at 5-HT_{1A}R and 5-HT_{2C}R and found substantially weaker β -arrestin2 recruitment at these subtypes (Supplementary Fig. 6C), confirming a lack of biased agonism at these receptors. Furthermore, weak activity was confirmed in 5-HT_{2A}-G11 dissociation, 5-HT_{2A/2B/2C}-Gq/11-mediated calcium flux activity, and at all human 5-HT GPCRs measuring G protein agonism by BRET confirmed with 25N-N1-Nap (16) and 25N-NBPh (17) (Supplementary Fig. 6D,E, F). Interestingly, the β -arrestin-biased agonists showed partial antagonism of 5-HT_{2A}-Gq activity, similarly found with the non-

psychedelic 2-Br-LSD¹¹, and also showed baseline inhibition in 5-HT_{2A}R Gq/11-mediated calcium flux traces at long time points, suggestive of potential β -arrestin2-mediated desensitization in this cell system (Supplementary Fig. 6E-G). We also confirmed and validated β -arrestin2 bias using our previously established kinetic BRET assay, which consistently showed robust β -arrestin2 and weak Gq activities for 25N-N1-Nap (16) and 25N-NBPh (17) at all time points tested (Supplementary Fig. 6H).

Encouraged by the progress made identifying β -arrestin-biased 5-HT_{2A}R agonists, we examined the binding mode of 25N-N1-Nap (16) at the Gq-bound cryo-EM 5-HT_{2A}R structure (PDB: 6WHA) using IFD (Supplementary Fig. 5). Binding poses using RMSD as a metric were clustered to reveal key interactions with the conserved salt bridge to Asp155^{3,32} placed 25N-N1-Nap (16) in a similar pose as the 25CN-NBOH structure (Supplementary Table 20; Supplementary Fig. 5). Importantly, in the flexible docking, the *N*-naphthyl ring of 25N-N1-Nap (16) is wedged near W336^{6,48}, a highly conserved residue in class A GPCRs (Supplementary Fig. 5). W336^{6,48}, sometimes called the “toggle switch”, is implicated in GPCR activation and signaling bias, with distinct W6.48 rotamer conformations occurring in activated and non-activated GPCR structures³²⁻³⁵, including the 25CN-NBOH cryo-EM structure¹⁸. Given the close proximity and added steric bulk observed in this region with biased agonists like 25N-N1-Nap (16), and based on the electrostatic SAR, we hypothesized the weak Gq activity and β -arrestin bias are dependent, in part, on interactions with W336^{6,48}.

GPCR crystal and cryo-EM structures only show a “snapshot” of activation and are highly dependent on their ternary complex composition and intracellular binding partners. Therefore, we performed molecular dynamics (MD) to investigate interactions between 25N-N1-Nap (16) and 5-HT_{2A}R, focusing especially on residue W336^{6,48}, and compared the results to simulations performed with 25CN-NBOH in the cryo-EM structure. Across 250 ns simulations, time-dependent intermolecular interaction energies were maintained between each ligand and the anchoring orthosteric residues D155^{3,32}, F339^{6,51} and F340^{6,52} (Supplementary Fig. 7, 8). Comparison of the trajectories reveals that the 25N-N1-Nap simulation has features intermediate between the inactive (6WH4) and active (25CN-NBOH) conformations (Fig. 3B,C). For example, in the final frame of the simulation, the outward swing of TM6, with 25N-N1-Nap (16), relative to the inactive state (6WH4) is lesser than that of 25CN-NBOH (7.30° vs. 15.49°) (Fig. 3D). A clear difference in the W336^{6,48} χ_2 angle frequency was observed between the 25CN-NBOH and 25N-N1-Nap simulations, where 25N-N1-Nap (16) showed a preference for W336^{6,48} χ_2 angle down (centered at -15.6°), and 25CN-NBOH showed a preference

for W336^{6.48} χ_2 angle up (66.2°) in the active rotamer conformation (Fig. 3E), similar to the active state cryo-EM structure¹⁸. Interestingly, in the 25N-N1-Nap simulation, W336^{6.48} initially toggles further downward into the pocket and mostly remains in this orientation throughout the simulation, likely to accommodate the larger *N*-naphthyl ring in 25N-N1-Nap (16), and is distinct from the W336^{6.48} χ_2 angles in active- (6WHA) and inactive-state 5-HT_{2A}R structures (Fig. 3B,E; e.g., PDB structures 6WGT, 6A94, 6A93, 6WH4; compare Supplementary Tables 21 and 22).

To verify the role of W336^{6.48} in 5-HT_{2A}R biased signaling, we constructed conservative mutations, W336^{6.48}Y and W336^{6.48}L, designed to increase space and accommodate the larger substituents in 25N β -arrestin-biased ligands. Although the W336^{6.48}L mutant exhibited reduced Gq dissociation and impaired β -arrestin recruitment (Fig. S3F), preventing further experimental use, the W336^{6.48}Y mutant showed robust Gq and β -arrestin recruitment and was used in subsequent experiments (Supplementary Fig. 6I). When 25N-N1-Nap (16) and 25N-NBPh (17) were tested at the W336^{6.48}Y mutant, the Gq efficacy recovered substantially, resulting in balanced agonist activity similar to 25N-NBOMe (4) (Fig. 3F). The recovery of Gq activity likely results from the increased space created by a smaller size Tyr residue at position 6.48, allowing the “toggle switch” to move dynamically to initiate Gq-bound activation states. The mutagenesis data support the hypothesis that the W336^{6.48} toggle switch plays an important role in the signaling bias of 25N-N1-Nap (16) and 25N-NBPh (17), with steric bulk on the *N*-benzyl ring forcing W336^{6.48} into a unique rotamer conformation, making it less likely that Gq-bound conformations will arise while preserving β -arrestin-preferring conformational states.

β -Arrestin-biased 5-HT_{2A} agonists lack psychedelic potential

The HTR is commonly used as a behavioral proxy for psychedelic effects because non-psychedelic 5-HT_{2A}R agonists do not induce head twitches³⁶, and because there is a robust correlation between HTR activity in mice and potency to induce psychedelic effects in humans and discriminative stimulus effects in rats⁹. To assess psychedelic potential for the 25N series, seventeen compounds were tested in the HTR assay based on their diverse range of Gq and β -arrestin efficacies. Male mice were used to maintain consistency with the validation experiments supporting use of the HTR as a cross-species readout of psychedelic potential^{9,36} and to leverage the large dataset of HTR dose-response data previously generated in male mice. When tested in C57BL/6J mice, eleven of the compounds increased HTR counts significantly over baseline levels (Supplementary

Tables 15 and 16). Not surprisingly, 25N-NBOMe (4), which acts as a psychedelic in humans³⁷, produced a potent HTR response consistent with this effect (Fig. 4A). By contrast, the β -arrestin2-biased compounds 25N-N1-Nap (16), 25N-NBPh (17) and 25N-NB-2-OH-3-Me (18) failed to induce the HTR (Fig. 4B-D; Supplementary Tables 15,16), suggesting Gq efficacy is necessary for psychedelic potential. To confirm the β -arrestin2-biased agonists can partition into the brain and engage central 5-HT_{2A}R necessary for the HTR, we pretreated mice with those compounds, which subsequently blocked the HTR induced by psychedelic 5-HT_{2A}R agonist DOI (Fig. 4E-H). 25N-NBPh (17) had lower potency than 25N-N1-Nap (16) in the blockade experiments, which we believe is due to pharmacokinetic differences limiting its CNS distribution, potentially reflecting its higher cLogP (4.8 vs. 4.5, respectively). We thus focused on 25N-N1-Nap (16) in subsequent experiments. As expected, 25N-N1-Nap (16) and 25N-NBPh (17) antagonized 5-HT_{2A}R-Gq signaling in vitro with potency similar to the 5-HT_{2A}R-selective antagonist M100907 (Fig. 4I). Given the potential for species differences, which is evident for rodent versus human 5-HT_{2A}R^{38,39}, we verified that the β -arrestin bias exhibited by 25N-N1-Nap (16) and 25N-NBPh (17) is preserved at mouse 5-HT_{2A}R (Supplementary Fig. 9A).

To confirm that β -arrestin-biased 5-HT_{2A}R agonists do not induce the HTR and that this profile is not specific to the 25N series, we synthesized and tested *N*-naphthyl and *N*-biphenyl derivatives of other phenethylamine 5-HT_{2A}R agonists. Similar to the previous β -arrestin-biased compounds, these compounds exhibited weak Gq efficacy but had robust efficacy for β -arrestin2 recruitment (Supplementary Fig. 9B; Supplementary Table 13 and 14). When evaluated in mice, 25O-N1-Nap (28) and 2C2-N1-Nap (29) failed to induce head twitches (Supplementary Fig. 9C) but fully blocked the HTR induced by DOI (Supplementary Fig. 9D), indicating brain penetration. In summary, five different β -arrestin2-biased 5-HT_{2A}R agonists did not induce the HTR when tested at doses that block the response to a balanced agonist, confirming this strategy can consistently generate β -arrestin2-biased 5-HT_{2A}R agonists devoid of psychedelic potential.

5-HT_{2A}-Gq signaling predicts psychedelic potential

Although the 5-HT_{2A}R signaling pathways responsible for psychedelic potential have been previously investigated, the results were inconclusive⁴⁰⁻⁴². To assess further the involvement of 5-HT_{2A}R Gq and β -arrestin2 signaling in the HTR, correlation analyses were performed using the 25N series, which contains a mixture of HTR-active and inactive compounds. For the 25N compounds with Gq and β -arrestin2 data ($n=14$),

there was robust correlation between HTR magnitude (the maximum number of HTR induced by each drug in counts/minute) and 5-HT_{2A}R-Gq efficacy (%5-HT E_{MAX}; $R_S = 0.8242$, $p = 0.0005$; Fig. 5A). By contrast, HTR magnitude was not correlated with β -arrestin2 recruitment ($R_S = -0.01538$, $p = 0.9638$; Fig. 5B). Notably, the relationship between 5-HT_{2A}R-Gq efficacy and HTR magnitude was nonlinear and none of the 25N derivatives with Gq E_{MAX} values <70% induced the HTR, potentially indicating that 5-HT_{2A}R efficacy must exceed a strong Gq agonist threshold level in order to induce the behavior. Similar to the BRET Gq data, the magnitude of the HTR induced by 25N derivatives is correlated with their 5-HT_{2A}R Gq/11-mediated calcium flux response ($R_S = 0.8175$, $p = 0.0002$; Supplementary Fig. 10A) and only the compounds with Gq-mediated calcium flux efficacy exceeding 70% 5-HT E_{MAX} induced head twitches, providing further evidence that 5-HT_{2A}R-Gq efficacy is necessary for psychedelic potential.

We also tested whether a similar relationship exists for drug potencies (ED₅₀) in HTR experiments. Although the *in vivo* potencies of psychedelic drugs are known to be correlated with their *in vitro* potencies at 5-HT_{2A}R⁴³⁻⁴⁵, it is not clear whether a similar relationship exists for the HTR. Notably, we observed robust and highly significant correlations between potencies in the HTR assay and *in vitro* 5-HT_{2A}R potency measures, including binding affinities (K_i) measured using [³H]-ketanserin, and functional potencies (EC₅₀) for activating Gq and β -arrestin2 via 5-HT_{2A}R (Supplementary Fig. 10B-F). Similar correlation results were obtained for 5-HT_{2A}R Gq and β -arrestin2 pathways, which is not surprising because the rank-order potencies of 5-HT_{2A}R agonists for Gq and β -arrestin2 are similar, whereas agonist efficacies often diverge across those two pathways. Overall, these results are consistent with the known role of 5-HT_{2A}R in the HTR and show a good correlation between *in vitro* and *in vivo* potency measures, but they do not link the HTR to a particular transducer pathway because they fail to account for 5-HT_{2A}R efficacy at each respective transducer.

Encouraged by results obtained with the 25N series, we examined whether the magnitude of the HTR produced by other psychedelics is correlated with their 5-HT_{2A}R-Gq efficacy. To test this hypothesis, we compared 5-HT_{2A}R efficacies and HTR magnitude for 24 phenethylamine psychedelics (Supplementary Fig. 11; Supplementary Tables 11, 12 and 18), which tend to have greater 5-HT₂ selectivity compared to other scaffolds¹⁰. Our results show a significant positive relationship between HTR magnitude and 5-HT_{2A}R-Gq efficacy ($R_S = 0.7339$, $p < 0.0001$; Fig. 5C). Conversely, there is not a significant correlation between HTR magnitude and 5-HT_{2A}R- β -arrestin2 efficacy ($R_S = 0.34$, $p = 0.104$; Fig. 5D). Consistent with the 25N series

data, all of the tested psychedelics activated Gq with relatively high efficacy and the trendline between HTR magnitude and Gq efficacy indicates a minimum of 70% 5-HT_{2A}R-Gq efficacy (%5-HT E_{MAX}). In summary, our results indicate there is a threshold level of 5-HT_{2A}R-Gq efficacy required for psychedelic-like activity.

To test the hypothesis that HTR activity and psychedelic potential can be predicted based on the existence of a 5-HT_{2A}R-Gq efficacy threshold, we synthesized *N*-benzyl derivatives of other phenethylamines and made predictions about their HTR activity based on their 5-HT_{2A}R-Gq efficacy (Fig. 5E). We synthesized and tested 2C2-NBOMe (31) (E_{MAX} = 98.4%), 25O-NBOMe (32) (E_{MAX} = 99.9%), and 25O-NBcP (33) (E_{MAX} = 96.3%), which are highly efficacious 5-HT_{2A}R-Gq agonists (Supplementary Fig. 10G-I) and would be predicted to induce the HTR. By contrast, 25D-N1-Nap (26) (E_{MAX} = 34.3%), 25O-NB-3-I (34) (E_{MAX} = 51.7%), and 25O-NBPh-10'-OH (35) (E_{MAX} = 60.8%) have efficacy <70% (Supplementary Fig. 10J-L) and were predicted to be inactive in HTR. Indeed, robust HTR responses were measured for 2C2-NBOMe (31), 25O-NBOMe (32), and 25O-NBcP (33), but not for weaker Gq agonists, 25D-N1-Nap (26), 25O-NB-3-I (34), and 25O-NBPh-10'-OH (35) (Fig. 5F-K; Supplementary Table 19). These results show that the ability of 5-HT_{2A}R agonists to induce head twitches can be predicted based on their 5-HT_{2A}R-Gq efficacy.

To directly test the involvement of 5-HT_{2A}R-Gq signaling in the HTR, we evaluated whether inhibition of Gq signaling can block the HTR. Because the use of signaling inhibitors can potentially be confounded by off-target effects, we targeted two different proteins within the Gq-PLC effector pathway to generate convergent evidence. YM-254890 selectively inhibits Gq/11⁴⁶ and is effective in mice when administered systemically or centrally⁴⁷. Intracranial (ICV) pretreatment with YM-254890 blocked the HTR induced by DOI (Fig. 5L). We also tested the phosphoinositide-selective PLC inhibitor edelfosine⁴⁸, which is brain penetrant in mice, with a brain/plasma ratio of ~0.5 after systemic administration⁴⁹. Edelfosine blocked the HTR induced by 25N-NBOMe (4) and DOI (Fig. 5M). These results strongly support the conclusion that the HTR induced by psychedelics is dependent on activation of the Gq-PLC pathway. This dependence on 5-HT_{2A}-Gq signaling is supported by the lack of a HTR with 25N-N1-Nap (16) and other β -arrestin2-biased 5-HT_{2A}R agonists, and it does not appear that activation of β -arrestin2 by 5-HT_{2A}R agonists is sufficient to induce head twitches. Although YM-254890 inhibited the response to DOI to a greater degree than Gq gene deletion⁴², the ability of both manipulations to dampen the response to DOI strongly supports our conclusions that 5-HT_{2A}R-Gq signaling is necessary for the HTR and therefore psychedelic potential.

Non-psychedelics do not achieve 5-HT_{2A} Gq-signaling efficacy threshold

The existence of an efficacy threshold for activity is intriguing because it potentially explains why certain 5-HT_{2A}R agonists such as lisuride fail to induce head twitches in mice and psychedelic effects in humans. To evaluate that possibility, we compared the activity of four psychedelic and four non-psychedelic 5-HT_{2A}R agonists in BRET assays and HTR experiments. Clinical studies have confirmed that lisuride⁵⁰⁻⁵³, 2-Br-LSD^{54,55,56}, and 6-F-DET⁵⁷ lack psychedelic effects in humans; 6-MeO-DMT has not been evaluated clinically but does not substitute in rats trained to discriminate a psychedelic drug⁵⁸. The psychedelic 5-HT_{2A}R agonists LSD, psilocin, 5-MeO-DMT, and DET activate 5-HT_{2A}R-Gq signaling with E_{MAX} ranging from 74.1–98.8% (Fig. 6A) and induce the HTR (Fig. 6B). Conversely, the non-psychedelic 5-HT_{2A}R agonists lisuride, 2-Br-LSD, 6-F-DET, and 6-MeO-DMT activate 5-HT_{2A}R-Gq signaling with E_{MAX} <70% (Fig. 6A) and do not induce head twitches (Fig. 6B). For the eight compounds, there was a significant positive correlation ($R = 0.8948$, $p = 0.0027$) between HTR magnitude and 5-HT_{2A}R-Gq E_{MAX} (Fig. 6C). These results are consistent with the predicted activity threshold and demonstrate that the relationship between HTR magnitude and 5-HT_{2A}R-Gq efficacy extends to tryptamines and lysergamides. In summary, lisuride, 2-Br-LSD, 6-F-DET, and 6-MeO-DMT are likely non-psychedelic because they have relatively weak Gq efficacy at 5-HT_{2A}R.

In vitro and *in vivo* effects of β -arrestin-biased 5-HT_{2A} agonists

An intriguing question raised by our results is how β -arrestin-biased 5-HT_{2A}R agonists differ from 5-HT_{2A}R antagonists. One hallmark of β -arrestin-biased agonists is the induction of arrestin-dependent internalization and downregulation, which contributes to drug tolerance⁵⁹. To determine whether 25N-N1-Nap (16) and 25N-NBPh (17) induce β -arrestin2-dependent receptor internalization, which would further support their β -arrestin-biased agonist profile, we conducted NanoBit internalization assays^{60,61} that utilize a minimally tagged N-terminal HiBiT-tagged 5-HT_{2A}R and a membrane impermeable LgBit Nanoluc complementation fragment to measure surface expression loss (Fig. 7A). In experiments where untagged β -arrestin2 was co-expressed (similar conditions to β -arrestin2 BRET assays), 5-HT and DOI induced a strong internalization after 60 minutes. 25N-N1-Nap (16) and 25N-NBPh (17) also induced robust internalization, similar to their potencies in β -arrestin2 recruitment assays (Fig. 7B). By contrast, the 5-HT_{2A}R antagonist/inverse agonist pimavanserin (PIM) did not induce internalization, suggesting that β -arrestin-biased 5-HT_{2A}R agonists are distinct from

pimavanserin in their ability to downregulate 5-HT_{2A}R. Previous work in whole cell and *in vivo* systems revealed that some 5-HT_{2A}R antagonists cause atypical 5-HT_{2A}R internalization, with several proposed mechanisms including direct 5-HT_{2A}R mediated, downstream, and off-target effects^{62,63}, though interestingly other 5-HT_{2A}R antagonists such as eplivanserin (SR 46349B) upregulate 5-HT_{2A}R in mice⁶⁴. Thus, how these 5-HT_{2A}R ligands affect *in vivo* receptor expression may be influenced by several factors and requires further study.

5-HT_{2A}R agonists are known to cause receptor downregulation and tolerance or tachyphylaxis⁶⁵. We tested whether β -arrestin2-biased 5-HT_{2A}R agonists induce tolerance *in vivo*, based on the rationale that tolerance could potentially act as an *in vivo* readout of β -arrestin2 recruitment. Our hypothesis was that repeated treatment with 25N-N1-Nap (16) would induce tolerance similar to the pathway-balanced 5-HT_{2A}R agonist DOI, whereas an inverse agonist like PIM which lacks β -arrestin2 recruitment (Fig 7A) would not. The results (Fig. 7D) were normalized to the vehicle control group to facilitate comparison of the amount of tachyphylaxis induced by the three 5-HT_{2A}R ligands. Once daily administration of 25N-N1-Nap (16) or DOI to mice for five consecutive days reduced the ability of a challenge dose of DOI administered 24 h later to induce the HTR (Fig. 7C,D). Conversely, the response to DOI was not altered in mice treated repeatedly with a dose of the 5-HT_{2A}R antagonist PIM that is capable of blocking the acute behavioral response to DOI (Fig. 7E). Hence, repeated administration of 25N-N1-Nap (16), DOI, and PIM produced effects in mice that closely parallel the *in vitro* internalization data. Based on these results, β -arrestin2 may play a role in the tachyphylaxis that occurs after repeated administration of 5-HT_{2A}R agonists.

Finally, to assess whether β -arrestin-biased 5-HT_{2A}R agonists may have similar therapeutic potential as 5-HT_{2A}R antagonists/inverse agonists, we tested whether 25N-N1-Nap (16) can antagonize PCP-induced hyperactivity in mice. 5-HT_{2A}R antagonists are highly effective at blocking the hyperlocomotion induced by NMDA receptor antagonists such as PCP and MK-801^{17,66}. 25N-N1-Nap (16) blocked the hyperactivity induced by PCP in mice when tested at a dose that had no effect on baseline activity (Fig. 7F). We confirmed that the 5-HT_{2A}-selective antagonist M100907 has a similar effect on reducing PCP-induced hyperactivity in mice (Fig. 7G) consistent with an antipsychotic-like profile.

Discussion

Our ultimate aim was to elucidate which 5-HT_{2A}R-coupled transducer pathway is responsible for psychedelic activity. Here we show that rational and structure-based design can be leveraged to develop 5-HT_{2A}R-selective compounds with a wide-range of functional activities, including β -arrestin2-biased agonists. Docking, MD, and mutagenesis revealed that W336^{6,48} plays a key role in the mechanism of β -arrestin2-biased agonists. Finally, β -arrestin2-biased 5-HT_{2A}R agonists were used to probe the involvement of specific signaling pathways in the psychedelic potential of 5-HT_{2A}R agonists. The ability of 5-HT_{2A}R agonists to induce the HTR was found to be correlated with Gq efficacy but not β -arrestin2 recruitment. Compounds exhibiting a signaling bias for β -arrestin2 did not induce psychedelic-like behavioral effects, but were capable of blocking psychedelic-like behaviors *in vivo*. Overall, we identified multiple structural and chemical features of psychedelics that can be targeted to fine-tune 5-HT_{2A}R activity, potentially allowing the therapeutic efficacy and tolerability of 5-HT_{2A}R ligands to be optimized for various therapeutic indications including psychosis.

Although the specific signaling cascades mediating the HTR have not been conclusively identified, Gq and β -arrestin2 are clear candidates. Previous studies in constitutive knockout (KO) mice have attempted to address the role of Gq and β -arrestin2 in the HTR but did not yield conclusive results. Knocking out Gq attenuated but did not eliminate the HTR induced by DOI⁴², potentially because other Gq protein subtypes such as G11 may also be involved. HTR studies in β -arrestin2 KO mice have variously reported that the response to DOI is unaltered^{41,67}, the response to 5-MeO-DMT is enhanced⁶⁸, and the response to LSD is attenuated⁴⁰. Although the reason for these discrepancies is unknown, it could reflect altered membrane receptor trafficking in β -arrestin2 KO mice, leading to constitutive receptor desensitization and other adaptations. Given the lack of an effect of 25N-N1-Nap (16) and other β -arrestin2-biased 5-HT_{2A}R agonists in the HTR paradigm, activation of β -arrestin2 by 5-HT_{2A}R agonists does not appear to be sufficient to induce head twitches. Although β -arrestin2 may not be involved in the HTR, our findings do implicate β -arrestin2 in the tachyphylaxis that occurs after repeated administration of 5-HT_{2A}R agonists. Mice treated repeatedly with psychedelic drugs develop tolerance and cross-tolerance, potentially reflecting 5-HT_{2A}R downregulation⁶⁷. Similarly, repeated treatment with 25N-N1-Nap (16) induced a tolerance to a subsequent challenge dose of DOI, indicating β -arrestin2-biased agonists may also be capable of inducing 5-HT_{2A}R downregulation. Although it was recently reported that β -arrestin2 KO mice do show tolerance to DOI-induced HTR after repeated

treatment⁶⁷, the use of constitutive KOs to address the mechanisms of GPCR tolerance is not ideal because of potential adaptations that may occur to offset the loss of β -arrestin2 in a global genetic knock-out model.

One important result of these studies is the discovery of an apparent 5-HT_{2A}R efficacy threshold for induction of the HTR in mice. In addition to finding a robust and highly significant correlation between the magnitude of the HTR and multiple readouts of 5-HT_{2A}R-Gq efficacy, we found that compounds with a Gq E_{MAX} <70% do not induce the HTR. 5-HT_{2A}R efficacy was found to be correlated with HTR magnitude in previous studies of mixed 5-HT_{2A/2C} agonists^{69,70}, but those studies did not test enough compounds to identify a clear efficacy threshold for HTR activity. Since mice exhibit a baseline level of spontaneous HTR that is driven by basal 5-HT_{2A}R activation⁷¹, the existence of a threshold for HTR activity is not surprising because compounds with low efficacy may act as partial antagonists relative to endogenous 5-HT basal stimulation. A similar threshold may exist for psychedelic effects in humans because all of the psychedelics we tested (including LSD and tryptamines) activated 5-HT_{2A}R-Gq signaling with E_{MAX} >70%, whereas non-psychedelic analogs have lower efficacy (E_{MAX} <70%) and likely explain why the latter molecules do not induce the HTR in mice or psychedelic effects in humans. Consistent with our findings, lisuride (E_{MAX} = 48.6%) was reported to have substantially lower efficacy than LSD (E_{MAX} = 84.6%) or DOI (E_{MAX} = 81.3%) in a 5-HT_{2A}R-Gq calcium mobilization assay⁷². Although we did not test the putative non-psychedelic 5-HT_{2A}R agonist tabernathalog, it reportedly has E_{MAX} = 57% in a 5-HT_{2A}R calcium flux assay⁵, which may be too low to induce the HTR. These data have implications for drug development as it should be possible to identify 5-HT_{2A}R-Gq partial agonists that do not induce the HTR and lack strong psychedelic effects in humans but retain sufficient efficacy to induce therapeutic neurophysiological effects via 5-HT_{2A}R (e.g., induction of neuroplasticity). 2-Br-LSD seems to have a profile consistent with this hypothesis because it induces neuroplasticity via 5-HT_{2A}R even though its 5-HT_{2A}R-Gq E_{MAX} is subthreshold to induce the HTR¹¹. Based on these results, it should be possible to rationally design non-psychedelic 5-HT_{2A}R agonists with therapeutic potential by fine-tuning their 5-HT_{2A}R-Gq efficacy. In effect, partial 5-HT_{2A}R-Gq agonists may act as mixed agonist-antagonists, similar to buprenorphine and other opioid receptor partial agonists⁷³. The partial agonism of buprenorphine is believed to contribute to its superior safety profile and greater tolerability¹⁷. Future studies will also need to examine partial 5-HT_{2A}R-Gq agonists in preclinical disease models to assess whether they possess therapeutic-like activity, for example as rapid-acting antidepressants. The potential therapeutic utility of β -arrestin-biased 5-HT_{2A}R agonists needs

further study, but our findings suggest they mimic psychedelics in some ways (induction of cross-tolerance and 5-HT_{2A}R downregulation) but also produce antagonist-like effects (e.g. blockade of PCP hyperlocomotion and DOI-induced HTR). Potentially, β -arrestin-biased ligands may mimic the therapeutic effects of 5-HT_{2A}R antagonists with less potential to disrupt cognition, possibly improving their efficacy and tolerability.

Based on our results, ligand interactions with residue W336^{6,48} are an important predictor of agonists with weaker Gq efficacy but do not fully explain the β -arrestin bias exhibited by these compounds. Residue W6.48 is known to be critical in propagating conformational changes by altering the position of TM6 to impact the cytosolic transducer binding pockets and influence bias³⁴, but the change in W336^{6,48} in our 25N-N1-Nap (16) simulation can likely influence other trigger motifs (PIF and NPxxY), which may be important to preserving GPCR-arrestin recruitment. For example, an influence of W6.48 on the PIF/PIW motif and corresponding changes in TM6 orientation were observed in MD studies with bias at β_2 -adrenergic³², rhodopsin⁷⁴, MOR³⁴, 5-HT_{2C}R⁷⁵, S1PR1⁷⁶, and other GPCRs³⁵. Moreover, our MD results with the “partially active” TM6 orientation are intriguing given several arrestin-1 GPCR structures, including LSD-bound 5-HT_{2B}R structures⁷⁷, show a larger TM6 outward movement relative to the G protein-bound state, though differences may exist in the initial conformation recognized by the transducer and the resulting complex. Therefore, further structural studies are needed to identify other conformational changes involved in Gq versus arrestin-modulation of the binding pocket, especially with respect to these discovered biased ligands.

In conclusion, we have shown that psychedelic drugs activate both 5-HT_{2A}R-Gq and β -arrestin2 transducers, which led to us to design 5-HT_{2A}R-selective biased agonists to probe the signaling pathways necessary for psychedelic potential. These results indicate that a threshold level of Gq activation is necessary to produce psychedelic-like effects, as measured by the HTR, and that it is possible to predict psychedelic potential based on the degree of 5-HT_{2A}R-Gq efficacy. This study has implications for understanding the neurobiological basis of psychedelic effects and reveals strategies for designing non-psychedelic 5-HT_{2A}R agonists that can potentially be used as therapeutics.

METHODS

Synthesis Materials and Methods

N-benzyl-compounds were synthesized by reductive amination (using NaBH₄) of the pre-formed imine (in solution) obtained by treating the primary amine (e.g., 25N) with the respective aldehyde in dry (3 Å molecular sieves) methanol and THF in the presence of 3 Å molecular sieves in the dark under an argon atmosphere for at least 48 hours. Descriptions, including yields and analytical data including ¹H and ¹³C NMR chemical shift assignments, ¹H and ¹³C NMR spectra, HPLC traces are provided in the Supplementary document.

Intermediates and reagents for synthesis were purchased from Sigma-Aldrich (St Louis, MO, USA), AKSci, and Alfa Aesar. Reagents were generally 95% pure or greater. 200 proof ethyl alcohol was obtained from Pharmaco (Greenfield Global, CT, USA). Silica gel flash column chromatography was performed using Merck silica gel grade 9385 (230-400 mesh, 60 Å). Melting points were measured using a Digimelt A160 SRS digital melting point apparatus (Stanford Research Systems, Sunnyvale, CA, USA) using a ramp rate of 2 °C/min.

High Performance Liquid Chromatography (HPLC)

HPLC analyses were performed on an Agilent 1260 Infinity system that includes a 1260 quaternary pump VL, a 1260 ALS autosampler, a 1260 Thermostatted Column Compartment, and a DAD Multiple Wavelength Detector (Agilent Technologies, Santa Clara, CA, USA). Detection wavelengths were set at 220, 230, 254, and 280 nm but only 220 nm was used for analysis. A Zorbax Eclipse XDB-C18 analytical column (5 µm, 4.6 x 150 mm) from Agilent Technologies was used. Mobile phase A consisted of 10 mM aqueous ammonium formate buffer titrated to pH 4.5. Mobile phase B consisted of acetonitrile. The injection volume of samples was 10 µL, flow rate was 1.0 mL/min, and the column temperature was set at 25°C. Samples were prepared by preparing a 1 mg/mL solution in 1:1 A:B. All samples were injected in duplicate with a wash in between each run. Run time was 10 minutes with a mobile phase ratio (isocratic) of 1:1 for A:B. Chromatograms were analyzed using the Agilent ChemStation Software (Agilent Technologies). Purity values were calculated from area under the curves of the absorbance at 220 nm of any resulting peaks.

High Resolution Mass Spectrometry (HRMS)

HRMS data were obtained on a Thermo Orbitrap Exactive Mass Spectrometer with an Orbitrap mass analyzer. The instrument was calibrated using electrospray ionization with Pierce™ LTQ ESI Positive Ion Calibration Solution from ThermoFisher Scientific. Samples were introduced into the instrument and ionized via an Atmospheric Solids Analysis Probe (ASAP). Data was analyzed in the Thermo Xcalibur Qual Browser software and identity was confirmed if <5 ppm error. Measurement parameters were as follows: Aux gas flow rate-8, Spray Voltage-3.50 kV, Capillary temperature-275°C, Capillary Voltage-25.00 V, Tube Lens Voltage-65.00 V, Skimmer Voltage-14.00 V, Heater Temperature-100°C.

Elemental Analysis

Elemental analysis (C, H, N) was run on select compounds by Galbraith Laboratories, Inc. (Knoxville, TN).

Nuclear Magnetic Resonance

¹H (400 MHz) and ¹³C NMR spectra (101 MHz) were obtained on the hydrochloride salts as a solution in anhydrous d₆-DMSO (~20 mg/mL) (>99.9% D, Sigma-Aldrich) on a Bruker Avance III with PA BBO 400S1 BBF-H-D-05 Z plus probe (Bruker Corporation, Billerica, MA, USA). Solvent (δ = 2.50 and 39.52 ppm for ¹H and ¹³C spectra respectively) was used for internal chemical shift references. ¹⁹F (376.5 MHz) NMR was run as described above using ~100 µL of trichlorofluoromethane (99%+, Sigma-Aldrich) as internal reference (δ = 0.0 ppm). Full NMR chemical shift assignments were made using chemical shift position, splitting patterns, ¹³C and ¹³C PENDANT or APT and hetero- and homo- 2-D experiments including HMQC or HSQC, HMBC and COSY (45° pulse tilt). A background water concentration of solvent (determined as integration ratio relative to solvent

shift) was also determined to check for water content (indicative of a hydrate) within the final salts for 25N compounds. Evidence of hydrates was not observed.

Hammett σ Constants

Hammett σ constants are provided in Supplementary Table 3.

Receptor Binding Experiments

Competition based receptor binding studies were performed by the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) using described methods⁷⁸. Target compounds were dissolved in DMSO and an initial screen performed to assess displacement of the radioligand at target receptors using a concentration of 10 μ M. Those compounds which showed >50% displacement of specific radioligand binding for a given receptor then underwent secondary screenings at varying concentrations to determine pK_i values. For the K_i experiments, compounds were run in triplicate on separate plates. Each plate contained a known ligand of the receptor as a positive control. Full experimental details are available in the NIMH PDSP assay protocol book. For all 5-HT subtypes, an N=3-4 was performed except where noted (Supplementary Table 8) and a mean pK_i and SEM was calculated using these replicate experiments. Affinities at off-targets are provided in Supplementary Table 9,10.

Gq-Dissociation and β -arrestin2 recruitment BRET assays

To measure 5-HT receptor-mediated β -Arrestin2 recruitment as measured by BRET¹, HEK293T cells (ATCC CRL-11268; mycoplasma-free) were subcultured in DMEM supplemented with 10% dialyzed FBS (Omega Scientific) and were co-transfected in a 1:15 ratio with human or mouse 5-HT receptors containing C-terminal fused *renilla* luciferase (*RLuc8*), and a Venus-tagged N-terminal β -arrestin2 using 3:1 ratio of TransIT-2020 (Mirus). 5-HT_{2A} receptor mutants were designed and performed using Q5 mutagenesis kit (New England Biolabs). All DNA was sequence verified using Sanger nucleotide sequencing (Retrogen, San Diego, CA). To measure 5-HT receptor-mediated Gq activation via Gq/ γ 1 dissociation as measured by BRET², HEK293T cells were subcultured in DMEM supplemented with 10% dialyzed FBS and were co-transfected in a 1:1:1:1 ratio with *RLuc8*-fused human Gq (Gq-*RLuc8*), a GFP²-fused to the C-terminus of human G γ 1 (G γ 1-GFP²), human G β 1, and 5-HT receptor using TransIT-2020, as described previously⁷⁹. After at least 18-24 hours, transfected cells were plated in poly-lysine coated 96-well white clear bottom cell culture plates in DMEM containing 1% dialyzed FBS at a density of 25-40,000 cells in 200 μ L per well and incubated overnight. The next day, media was decanted and cells were washed with 60 μ L of drug buffer (1 $\times$ HBSS, 20 mM HEPES, pH 7.4), then 60 μ L of drug buffer was added per well. Cells were pre-incubated at in a humidified atmosphere at 37°C before receiving drug stimulation. Drug stimulation utilized 30 μ L addition of drug (3X) diluted in McCorvy buffer (1 $\times$ HBSS, 20 mM HEPES, pH 7.4, supplemented with 0.3% BSA fatty acid free, 0.03% ascorbic acid) and plates were incubated at indicated time and temperatures. Substrate addition occurred 15 minutes before reading and utilized 10 μ L of the *RLuc* substrate, either coelenterazine h for β -Arrestin2 recruitment BRET¹ or coelenterazine 400a for Gq dissociation BRET² (Prolume/Nanolight, 5 μ M final concentration) and was added per well. Plates were read for luminescence at 485 nm and fluorescent eYFP emission at 530 nm for BRET¹ and at 400 nm and fluorescent GFP² emission at 510 nm for BRET² at 1 second per well using a Mithras LB940 (Berthold) or a PheraStar FSX (BMGLabTech). The BRET ratios of fluorescence/luminescence were calculated per well and were plotted as a function of drug concentration using Graphpad Prism 5 or 9 (Graphpad Software Inc., San Diego, CA). Data were normalized to % 5-HT stimulation and analyzed using nonlinear regression "log(agonist) vs. response" to yield Emax and EC₅₀ parameter estimates.

Calcium Flux Assays

Stably expressing 5-HT receptor Flp-In 293 T-Rex Tetracycline inducible system (Invitrogen, mycoplasma-free) were used for calcium flux assays, as described and utilized previously⁸⁰. Cell lines were maintained in DMEM containing 10% FBS, 10 μ g/mL Blasticidin (Invivogen), and 100 μ g/mL Hygromycin B (GoldBio). Day before

the assay, receptor expression was induced with tetracycline (2μL/mL) and seeded into 384-well poly-L-lysine-coated black plates at a density of 7,500 cells/well in DMEM containing 1% dialyzed FBS. On the day of the assay, the cells were incubated with Fluo-4 Direct dye (Invitrogen, 20 μL/well) for 1 h at 37°C, which was reconstituted in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) containing 2.5 mM probenecid. After dye load, cells were allowed to equilibrate to room temperature for 15 minutes, and then placed in a FLIPR^{TETRA} fluorescence imaging plate reader (Molecular Devices). Drug dilutions were prepared at 5X final concentration in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) supplemented with 0.3% BSA fatty-acid free and 0.03% ascorbic acid. Drug dilutions were aliquoted into 384-well plastic plates and placed in the FLIPR^{TETRA} for drug stimulation. Fluorescence for the FLIPR^{TETRA} were programmed to read baseline fluorescence for 10 s (1 read/s), and afterward 5 μL of drug per well was added and read for a total of 5-10 min (1 read/s). Fluorescence in each well was normalized to the average of the first 10 reads for baseline fluorescence, and then either maximum-fold peak increase over basal or area under the curve (AUC) was calculated. Either peak or AUC was plotted as a function of drug concentration, and data were normalized to percent 5-HT stimulation. Data was plotted and non-linear regression was performed using “log(agonist) vs. response” in Graphpad Prism 9 to yield E_{max} and EC₅₀ parameter estimates.

Surface Expression/Internalization Experiments

Surface expression was measured using a HiBit-tagged 5-HT_{2A} receptor and the Nano-Glo HiBit Extracellular Detection System (Promega). N-terminal HiBit-tagged human 5-HT_{2A} receptor was cloned into pcDNA3.1 using Gibson Assembly. HEK293T cells (ATCC CRL-11268; mycoplasma-free) were transfected into 10-cm tissue culture dishes in a 1:15 ratio of HiBit-tagged human 5-HT_{2A} receptor: human β-Arrestin2 (cDNA Resource Center; www.cDNA.org). Cells were transfected in DMEM 10% dFBS and the next day, cells were plated into either poly-L-lysine-coated 96-well white assay plates (Grenier Bio-One). On the day of the assay, plates were decanted and HEPES-buffered DMEM without phenol-red (Invitrogen) was added per well. Plates were allowed to equilibrate at 37°C in a humidified incubator before receiving drug stimulation. Compounds (including 5-HT as control) were serially diluted in McCorvy buffer (20 mM HEPES-buffered HBSS, pH 7.4 supplemented with 0.3% BSA fatty-acid free and 0.03% ascorbic acid), and dilutions were added to plates in duplicate (96). Plates were allowed to incubate at 37°C for 1 hour in a humidified incubator or a specified time point. Approximately 15 minutes before reading, LgBit and coelenterazine h (5 μM final concentration) were added to each well. Plates were sealed to prevent evaporation and read on either a PheraStar FSX (BMB Lab Tech) or Mithras LB940 (Berthold Technologies) at 485 nm at 37°C for time-capture quantification of internalization or loss of surface expression. Luminescence was plotted as a function of drug concentration using Graphpad Prism 5 or 9 (Graphpad Software Inc., San Diego, CA). Data were analyzed using nonlinear regression “log(agonist) vs. response” to yield E_{max} and EC₅₀ parameter estimates and normalized to % 5-HT surface expression, which a full concentration-response curve was present on every plate.

Induced fit docking

Docking simulations of six of the 25N ligands, selected to assess the binding modes and provide potential insight into the SAR around signaling or receptor selectivity, were carried out against the active state human 5-HT_{2A} receptor (PDB: 6WHA) using the Induced-Fit Docking (IFD) protocol⁸¹ of the Schrodinger Suite (2020a). IFD was run with extended sampling enabled, using the default setting of residues within 5 Å of the experimental ligand (25N-NBCN) and other parameters maintained at their default values, and ligand structures processed using the LIGPREP tool (target pH of 7) of the Schrödinger (release 2020c). Poses generated in the IFD runs were analyzed using a custom Python script with PyMol visualization application (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC).

Estimation of ring substituent effects on molecular electrostatic potential

A series of model compounds were constructed that included only the benzylamine or naphthylamine portion of the corresponding ligand structure. Quantum mechanical optimization of the model compounds, in both neutral

and cationic forms, was carried out using density functional theory (DFT) with the Jaguar tool of the Schrodinger suite using the B3LYP functional and 6-311g**++ basis set, with the exceptions of the models for 25N-NBI, where the halogen atom was not supported, and a smaller basis (3-21g**++) was substituted. We computed Hirshfeld partial atomic charges (Supplementary Table 4) for the model compounds using the optimized wavefunctions as a proxy for overall MEP. Hirshfeld charges are computed from a spatial partitioning of the electron density, and have been shown to correlate well with a variety of properties of aromatic molecules⁸².

Molecular Dynamics (MD) Simulations

Simulations were performed for each of two ligands (25CN-NBOH or 25N-N1-Nap (16) in complex with the human 5-HT_{2A} serotonin receptor in a lipid bilayer of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and SPC water with enough Cl⁻ and Na⁺ ions to neutralize the system at biologic salinity (0.15 M ionic strength). For the 25CN-NBOH system a model of the protein-ligand part of the system was made from chain A of the 6WHA PDB entry, downloaded from the OPM server⁸³. Missing extracellular loops were filled in with those from chain A of PDB entry 6WGT. Schrödinger's Protein Preparation Wizard⁸⁴ was employed to use Prime⁸⁵ to fill in missing side chains, and to use Epik⁸⁶ to select the appropriate tautomers and protonation states of the protein and ligand. Due to anticipated difficulty modeling the long ICL3, the helices of TM5 and TM6 were capped, along with the N and C termini, with polar terminating residues: COOH for residue Q262^{5,66} and NH₂ for I315^{6,27}. During pilot simulations, entanglement of polar sidechains in the membrane occurred. To prevent this, it was found necessary that the rotamers for the loops and capped termini whose sidechains would otherwise interact with the polar heads of the lipid molecules be manually adjusted to ensure adequate water solvation at the beginning of the simulation. This was achieved by maximizing the magnitude of atomic coordinate z of terminal side-chain atoms, where the z-axis is perpendicular to the membrane and z = 0 locates the middle of the bilayer. Another issue identified during preliminary simulations was that DPPC tails would intrude into the orthosteric pocket between helices TM4 and TM5, causing the nitrile end of the ligand to project up toward the extracellular side of the pocket. On careful inspection, it was discovered that there is a stable position for a water molecule among residues D120^{2,50}, S162^{3,39}, and N376^{7,49}. Manual introduction of a solvent molecule into this void volume successfully prevented lipid intrusion.

A disulfide bond between C148^{3,25} and C227^{45,50}¹⁸ was added to the topology, as well one between C349^{6,61} and C353^{EC13}. Each ligand was protonated at the basic nitrogen (as confirmed by Epik) and topology parameter files needed for subsequent dynamics simulation were determined using the ATB server [<https://atb.uq.edu.au/>]. Partial atomic charges for the ligands were computed via Schrödinger's Jaguar tool using the density-functional method (B3LYP-D3 functional, 6-31G** basis), with discrete charges derived from the geometry-optimized wavefunction using the Hirshfeld approach (Supplementary Table 4). The total protein comprised 278 residues with 2,849 atoms. The remaining system consisted of 6,933 water molecules, 29 Cl⁻ ions, 20 Na⁺ ions, and 88 DPPC molecules. 25CN-NBOH has 44 atoms. The total number of atoms in the system is 28,137. The orthorhombic initial system dimensions were 61.319 × 60.911 × 97.412 Å³.

The protein-ligand complex for 25N-N1-Nap (16) starts with the structure from the top-ranked pose determined by induced fit docking (IFD). A chimeric homology model was created in Maestro using the IFD structure as the template everywhere except at the missing loops; these are taken from the 25CN-NBOH-system. This resulting protein-25N-N1-Nap (16) homology model was superposed (using the positions of the TM C_αs) onto the protein-ligand complex in the full (water-ion-lipid-protein-ligand) unrelaxed construct built for the 25CN-NBOH simulation. The protein-25CN-NBOH complex was then removed and the 25N-N1-Nap (16)-protein complex substituted in its place. As the IFD docking involved minimal changes to backbone conformation, the resulting model for the 25N-N1-Nap (16) ligand had helix and loop positions nearly identical to those of the 25CN-NBOH model, permitting a direct structural substitution. That said, prior to any further computations, a restrained minimization was carried out with only the membrane/solvent system fully mobile, to remove any high-energy

interatomic overlaps that might have been inadvertently produced by the alignment and substitution. The 25N-N1-Nap (16) simulation comprised a total of 28,143 atoms (50 atoms for the ligand and otherwise identical to the 25CN-NBOH system). The orthorhombic initial system dimensions were $61.864 \times 61.453 \times 96.12 \text{ \AA}^3$.

Simulation protocols and analysis

Both sets of simulations had three phases: minimization (unrestrained steepest decent), equilibration, and a production run. The equilibration phases for both sets comprise a restrained NVT simulation followed by a restrained NPT one. In both, the protein and ligand atoms were restrained close to their initial positions by a harmonic potential with force constant $k = 1000 \text{ kJ/mol/nm}$ ($23.9 \text{ kcal/mol/\AA}$). Both production simulations were 250-ns NPT unrestrained MD simulations. The force field used was GROMOS96 54a7⁸⁷. The MD engine used was GROMACS v2021.2. The energy parameters in common between the 25CN-NBOH and the 25N-N1-Nap (16) simulations can be found in Supplementary Table 23. The parameters that vary between stages and systems can be found in Supplementary Table 24.

The χ_2 dihedral data were measured by GROMACS's chi command every 10 ps. The histogram bin width was one degree. Plots were made in Grace v5.1.25. The time-series heat maps of the pocket-ligand nonbonded interaction energy were made with Seaborn and Matplotlib. The data were calculated by GROMACS's mdrun command. The pocket residues were determined by Schrödinger's Maestro (all residues within 5 Å of the ligand). Protein cartoons and geometric measurements were made in VMD⁸⁸ and Maestro.

Animal Behavioral Experiments

Male C57BL/6J mice (6–8 weeks old) from Jackson Labs (Bar Harbor, ME, USA) were used for the behavioral experiments. The mice were housed on a reversed light-dark cycle (lights on at 1900 h, off at 0700 h,) in an AALAC-approved vivarium at the University of California San Diego. Mice were housed up to four per cage in a climate-controlled room and with food and water provided ad libitum except during behavioral testing. Testing was performed between 1000 and 1800 h (during the dark phase of the light-dark cycle). The studies were conducted in accordance with National Institutes Health (NIH) guidelines and were approved by the University of California San Diego Institutional Animal Care and Use Committee.

The drug solutions used for the behavioral experiments were prepared as follows: pimavanserin hemitartrate (MedChemExpress), 25C-NBOH hydrochloride, 3,4-dimethoxy-4-methylphenethylamine hydrochloride (desoxy), and 4-cyclopropyl-3,5-dimethoxyphenethylamine hydrochloride (CPM) were dissolved in sterile water; 6-fluoro-*N,N*-diethyltryptamine (6-F-DET; donated by the Usona Institute, Fitchburg, WI, USA) was dissolved in sterile water acidified with HCl to pH 5; YM-254,890 (FUJIFILM Wako Chemicals USA, Richmond, VA, USA) was dissolved in 100% dimethyl sulfoxide (DMSO); edelfosine (Tocris Bioscience, Minneapolis, MN, USA), ($\pm$)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (($\pm$)-DOI; Cayman Chemical, Ann Arbor, MI, USA), *R*-(–)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (*R*-(–)-DOI; donated by the National Institute on Drug Abuse, Rockville, MD, USA), phencyclidine hydrochloride (PCP; Sigma-Aldrich), *N,N*-diethyltryptamine fumarate (DET; donated by the National Institute on Drug Abuse, Rockville, MD, USA), 5-methoxy-*N,N*-dimethyltryptamine hemifumarate (5-MeO-DMT; donated by the National Institute on Drug Abuse, Rockville, MD, USA), 6-methoxy-*N,N*-dimethyltryptamine hydrochloride (6-MeO-DMT), 25N-NBOMe hydrochloride, and 25N-NB hydrochloride were dissolved in isotonic saline; 25C-NBMD hydrochloride was dissolved in sterile water containing 2% Tween-80 (v/v); 25N-NBOEt hydrochloride, 25N-NB-2-OH-3-Me hydrochloride, 25N-NBPh hydrochloride, 25O-N1-Nap hydrochloride, 2C2-N1-Nap hydrochloride, 25O-NBOMe hydrochloride, 25O-NBPh-10'-OH hydrochloride, 25O-NB-3-I hydrochloride, 25O-NBcP hydrochloride, 2C-N hydrochloride, and M100907 were dissolved in sterile water containing 5% Tween-80 (v/v); 25N-NBNO₂ hydrochloride was dissolved in sterile water containing 20% hydroxypropyl- β -cyclodextran (w/v); 25N-NBBR hydrochloride was dissolved in sterile water containing 5% Tween-80 (v/v) and 20% hydroxypropyl- β -cyclodextran (w/v); for the remaining 25N derivatives, the hydrochloride salts were dissolved in sterile water containing 1% Tween-80

(v/v). 25N derivatives, 25O-NBOMe, 25O-NBPh-10'-OH, 25O-NB-3-I, 25O-NBcP, 25O-N1-Nap, 2C2-NBOMe, 2C2-N1-Nap, and 25D-N1-Nap were injected SC (5 mL/kg or 10 mL/kg) to avoid first-pass effects and ensure stable pharmacokinetics; M100907 was injected SC (5 mL/kg); pimavanserin, edelfosine, *R*-(–)-DOI, (±)-DOI, 25C-NBOH, desoxy, CPM, 25C-NBMD, DET, 6-F-DET, 5-MeO-DMT, 6-MeO-DMT, and PCP were injected IP (5 mL/kg); YM-254,890 was injected into the lateral ventricle (2 µL) over 1 min. Slightly different procedures were used for the tolerance experiments (see below). HTR experiments with 1 mg/kg DOI were performed using either the racemate or the *R*-enantiomer as specified.

Assessment of the Head-Twitch Response

The head-twitch response (HTR) was assessed using a head-mounted neodymium magnet and a magnetometer detection coil, as described previously⁸⁹. The mice were allowed to recover from the magnet implantation surgeries for at least 1 week prior to behavioral testing. Mice were tested in multiple HTR experiments, with at least 7 days between studies to avoid carryover effects. HTR experiments were conducted in a well-lit room, and the mice were allowed to habituate to the room for at least 1 h prior to testing. Mice were tested in a 12.5-cm diameter glass cylinder surrounded by a magnetometer coil. Coil voltage was low-pass filtered (2 kHz), amplified, and digitized (20-kHz sampling rate) using a Powerlab (model /8SP or 8/35) with LabChart software (ADInstruments, Colorado Springs, CO, USA). Head twitches were identified in the recordings off-line by their waveform characteristics⁹⁰ or using artificial intelligence⁹¹. HTR counts were analyzed using one-way ANOVAs or one-way Welch ANOVAs (in cases where groups showed unequal variances). Tukey's test or Dunnett's T3 multiple comparisons test was used for *post hoc* comparisons. Significance was demonstrated by surpassing an α level of 0.05. Median effective doses (ED₅₀ values) and 95% confidence intervals for dose-response experiments were calculated by nonlinear regression (Prism 9.02, GraphPad Software, San Diego, CA, USA).

Assessment of PCP-Induced Locomotor Activity

The mouse behavioral pattern monitor (BPM) was used to assess locomotor activity⁹². Each mouse BPM chamber (San Diego Instruments, San Diego, CA, USA) is a transparent Plexiglas box with an opaque 30 × 60 cm floor, enclosed in a ventilated isolation box. The position of the mouse in x,y coordinates is recorded by a grid of 12 × 24 infrared photobeams located 1 cm above the floor. A second row of 16 photobeams (parallel to the long axis of the chamber, located 2.5 cm above the floor) is used to detect rearing behavior. Holepoking behavior is detected by 11 1.4-cm holes that are situated in the walls (3 holes in each long wall, 2 holes in each short wall) and the floor (3 holes); each hole is equipped with an infrared photobeam. The status of each photobeam is sampled every 55 ms and recorded for offline analysis. Mice were allowed to habituate to the testing room for at least 1 h prior to testing. For the BPM experiments, mice (*n*=6/group) were pretreated SC with test drug or vehicle, PCP (5 mg/kg) or vehicle was injected IP 10 minutes later, and then the mice were placed in the BPM chambers 10 minutes after the second injection and activity was recorded for 60 minutes. Locomotor activity was quantified as distance traveled, which was analyzed in 20-minute blocks using a three-way ANOVA, with pretreatment and treatment as between subject variables and time as a within-subject variable. Tukey's test was used for *post hoc* comparisons. Significance was demonstrated by surpassing an α level of 0.05.

Effect of Repeated Treatment with 5-HT_{2A} receptor ligands on Head-Twitch Response

In the first experiment, mice (*n*=6-7/group, 19 total) were injected SC (5 mL/kg) once daily with vehicle (water containing 5% Tween-80), 25N-N1-Nap hydrochloride (20 mg/kg), or (±)-DOI hydrochloride (10 mg/kg) for five consecutive days. Twenty-four hours later, all of the mice were challenged with an IP injection of 1 mg/kg (±)-DOI hydrochloride and then HTR activity was recorded for 40 minutes. In the second experiment, mice (*n*=6/group, 12 total) were injected IP (5 mL/kg) once daily with vehicle (water) or pimavanserin hemitartrate (1 mg/kg) for five consecutive days. Twenty-four hours later, all of the mice were challenged with an IP injection of 1 mg/kg (±)-DOI hydrochloride and then HTR activity was recorded for 40 minutes.

DATA AVAILABILITY

All data generated in this study are included in this article and the Supplementary information. Source data are provided with this paper.

CODE AVAILABILITY

No custom code was generated in this study.

References

- 1 Chi, T. & Gold, J. A. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. *J Neurol Sci* **411**, 116715, doi:10.1016/j.jns.2020.116715 (2020).
- 2 Romeo, B., Karila, L., Martelli, C. & Benyamina, A. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. *J Psychopharmacol* **34**, 1079-1085, doi:10.1177/0269881120919957 (2020).
- 3 Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacol Ther* **197**, 83-102, doi:10.1016/j.pharmthera.2018.11.010 (2019).
- 4 Mastinu, A. *et al.* The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. *Int J Mol Sci* **24**, doi:10.3390/ijms24021329 (2023).
- 5 Cameron, L. P. *et al.* A non-hallucinogenic psychedelic analogue with therapeutic potential. *Nature* **589**, 474-479, doi:10.1038/s41586-020-3008-z (2021).
- 6 Kaplan, A. L. *et al.* Bespoke library docking for 5-HT_{2A} receptor agonists with antidepressant activity. *Nature* **610**, 582-591, doi:10.1038/s41586-022-05258-z (2022).
- 7 Preller, K. H. *et al.* Effective connectivity changes in LSD-induced altered states of consciousness in humans. *Proceedings of the National Academy of Sciences of the United States of America* **116**, 2743-2748, doi:10.1073/pnas.1815129116 (2019).
- 8 Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* **9**, 3897-3902 (1998).
- 9 Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J. & Brandt, S. D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. *Neuropharmacology* **167**, 107933, doi:10.1016/j.neuropharm.2019.107933 (2020).
- 10 Halberstadt, A. L. & Geyer, M. A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. *Neuropharmacology* **61**, 364-381, doi:10.1016/j.neuropharm.2011.01.017 (2011).
- 11 Lewis, V. *et al.* A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. *Cell Rep* **42**, 112203, doi:10.1016/j.celrep.2023.112203 (2023).
- 12 McCorvy, J. D. & Roth, B. L. Structure and function of serotonin G protein-coupled receptors. *Pharmacol Ther* **150**, 129-142, doi:10.1016/j.pharmthera.2015.01.009 (2015).
- 13 Wacker, D. *et al.* Structural features for functional selectivity at serotonin receptors. *Science* **340**, 615-619, doi:10.1126/science.1232808 (2013).
- 14 Tan, L., Yan, W., McCorvy, J. D. & Cheng, J. Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. *Journal of medicinal chemistry* **61**, 9841-9878, doi:10.1021/acs.jmedchem.8b00435 (2018).
- 15 Kenakin, T. Biased Receptor Signaling in Drug Discovery. *Pharmacol Rev* **71**, 267-315, doi:10.1124/pr.118.016790 (2019).
- 16 Gan, T. J. & Wase, L. Oliceridine, a G protein-selective ligand at the mu-opioid receptor, for the management of moderate to severe acute pain. *Drugs Today (Barc)* **56**, 269-286, doi:10.1358/dot.2020.56.4.3107707 (2020).
- 17 Gillis, A. *et al.* Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. *Sci Signal* **13**, doi:10.1126/scisignal.aaz3140 (2020).
- 18 Kim, K. *et al.* Structure of a Hallucinogen-Activated Gq-Coupled 5-HT_{2A} Serotonin Receptor. *Cell* **182**, 1574-1588 e1519, doi:10.1016/j.cell.2020.08.024 (2020).
- 19 Wacker, D. *et al.* Crystal Structure of an LSD-Bound Human Serotonin Receptor. *Cell* **168**, 377-389 e312, doi:10.1016/j.cell.2016.12.033 (2017).
- 20 Kolb, P. *et al.* Community guidelines for GPCR ligand bias: IUPHAR review 32. *British journal of pharmacology* **179**, 3651-3674, doi:10.1111/bph.15811 (2022).
- 21 Klein Herenbrink, C. *et al.* The role of kinetic context in apparent biased agonism at GPCRs. *Nat Commun* **7**, 10842, doi:10.1038/ncomms10842 (2016).

- 22 Grundmann, M. & Kostenis, E. Temporal Bias: Time-Encoded Dynamic GPCR Signaling. *Trends Pharmacol Sci* **38**, 1110-1124, doi:10.1016/j.tips.2017.09.004 (2017).
- 23 Hansen, M. *et al.* Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT_{2A/2C} agonists. *ACS Chem Neurosci* **5**, 243-249, doi:10.1021/cn400216u (2014).
- 24 Juncosa, J. I., Jr. *et al.* Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT_{2A} serotonin receptor agonist ligands. *ACS Chem Neurosci* **4**, 96-109, doi:10.1021/cn3000668 (2013).
- 25 Acuna-Castillo, C. *et al.* Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. *Br J Pharmacol* **136**, 510-519, doi:10.1038/sj.bjp.0704747 (2002).
- 26 Moya, P. R. *et al.* Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)_{2A} and 5-HT_{2C} receptors. *J Pharmacol Exp Ther* **321**, 1054-1061, doi:10.1124/jpet.106.117507 (2007).
- 27 Braden, M. R., Parrish, J. C., Naylor, J. C. & Nichols, D. E. Molecular interaction of serotonin 5-HT_{2A} receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. *Mol Pharmacol* **70**, 1956-1964, doi:10.1124/mol.106.028720 (2006).
- 28 Hansen, M. *et al.* Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT_{2A/2C} partial agonists. *Bioorg Med Chem* **23**, 3933-3937, doi:10.1016/j.bmc.2014.12.011 (2015).
- 29 Marcher Rorsted, E., Jensen, A. A. & Kristensen, J. L. 25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor. *ChemMedChem* **16**, 3263-3270, doi:10.1002/cmdc.202100395 (2021).
- 30 Choudhary, M. S. *et al.* Differential ergoline and ergopeptine binding to 5-hydroxytryptamine_{2A} receptors: ergolines require an aromatic residue at position 340 for high affinity binding. *Mol Pharmacol* **47**, 450-457 (1995).
- 31 McCorvy, J. D. *et al.* Structural determinants of 5-HT_{2B} receptor activation and biased agonism. *Nature structural & molecular biology* **25**, 787-796, doi:10.1038/s41594-018-0116-7 (2018).
- 32 Chen, J. *et al.* Molecular Mechanisms of Diverse Activation Stimulated by Different Biased Agonists for the beta₂-Adrenergic Receptor. *Journal of chemical information and modeling* **62**, 5175-5192, doi:10.1021/acs.jcim.1c01016 (2022).
- 33 Suomivuori, C. M. *et al.* Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. *Science* **367**, 881-887, doi:10.1126/science.aaz0326 (2020).
- 34 Piekilna-Ciesielska, J. *et al.* Pharmacological Characterization of micro-Opioid Receptor Agonists with Biased G Protein or beta-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation. *Molecules* **26**, doi:10.3390/molecules26010013 (2020).
- 35 Hauser, A. S. *et al.* GPCR activation mechanisms across classes and macro/microscales. *Nature structural & molecular biology* **28**, 879-888, doi:10.1038/s41594-021-00674-7 (2021).
- 36 Gonzalez-Maeso, J. *et al.* Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. *Neuron* **53**, 439-452, doi:10.1016/j.neuron.2007.01.008 (2007).
- 37 Wood, D. M., Sedefov, R., Cunningham, A. & Dargan, P. I. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. *Clin Toxicol (Phila)* **53**, 85-92, doi:10.3109/15563650.2015.1004179 (2015).
- 38 Canal, C. E. *et al.* Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT_{2A} receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. *The Journal of pharmacology and experimental therapeutics* **347**, 705-716, doi:10.1124/jpet.113.208637 (2013).
- 39 Johnson, M. P., Loncharich, R. J., Baez, M. & Nelson, D. L. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. *Mol Pharmacol* **45**, 277-286 (1994).
- 40 Rodriguiz, R. M. *et al.* LSD-stimulated behaviors in mice require beta-arrestin 2 but not beta-arrestin 1. *Sci Rep* **11**, 17690, doi:10.1038/s41598-021-96736-3 (2021).

- 41 Schmid, C. L., Raehal, K. M. & Bohn, L. M. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. *Proc Natl Acad Sci U S A* **105**, 1079-1084, doi:10.1073/pnas.0708862105 (2008).
- 42 Garcia, E. E., Smith, R. L. & Sanders-Bush, E. Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. *Neuropharmacology* **52**, 1671-1677, doi:10.1016/j.neuropharm.2007.03.013 (2007).
- 43 Titeler, M., Lyon, R. A. & Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT₂ receptor as a site of action for LSD and phenylisopropylamine hallucinogens. *Psychopharmacology (Berl)* **94**, 213-216, doi:10.1007/BF00176847 (1988).
- 44 Glennon, R. A., Titeler, M. & McKenney, J. D. Evidence for 5-HT₂ involvement in the mechanism of action of hallucinogenic agents. *Life Sci* **35**, 2505-2511, doi:10.1016/0024-3205(84)90436-3 (1984).
- 45 Luethi, D. & Liechti, M. E. Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics. *Int J Neuropsychopharmacol* **21**, 926-931, doi:10.1093/ijnp/pyy047 (2018).
- 46 Takasaki, J. et al. A novel Galphaq/11-selective inhibitor. *J Biol Chem* **279**, 47438-47445, doi:10.1074/jbc.M408846200 (2004).
- 47 Marwari, S., Kowalski, C. & Martemyanov, K. A. Exploring pharmacological inhibition of Gq/11 as an analgesic strategy. *British journal of pharmacology*, doi:10.1111/bph.15935 (2022).
- 48 Powis, G. et al. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. *Cancer Res* **52**, 2835-2840 (1992).
- 49 Estella-Hermoso de Mendoza, A. et al. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. *Clin Cancer Res* **15**, 858-864, doi:10.1158/1078-0432.CCR-08-1654 (2009).
- 50 Verde, G. et al. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. *J Endocrinol Invest* **3**, 405-414, doi:10.1007/BF03349379 (1980).
- 51 Raffaelli, E., Jr., Martins, O. J. & dos Santos, P. D. F. A. Lisuride in cluster headache. *Headache* **23**, 117-121, doi:10.1111/j.1526-4610.1983.hed2303117.x (1983).
- 52 Gillin, J. C., Pulvirenti, L., Withers, N., Golshan, S. & Koob, G. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report. *Biol Psychiatry* **35**, 843-849, doi:10.1016/0006-3223(94)90019-1 (1994).
- 53 Schmidt, L. G., Kuhn, S., Smolka, M., Schmidt, K. & Rommelspacher, H. Lisuride, a dopamine D₂ receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. *Prog Neuropsychopharmacol Biol Psychiatry* **26**, 209-217, doi:10.1016/s0278-5846(01)00214-7 (2002).
- 54 Bertino, J. R., Klee, G. D. & Weintraub, W. Cholinesterase, dlysergic acid diethylamide, and 2-bromolysergic acid diethylamide. *J Clin Exp Psychopathol Q Rev Psychiatry Neurol* **20**, 218-222 (1959).
- 55 Karst, M., Halpern, J. H., Bernateck, M. & Passie, T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. *Cephalalgia* **30**, 1140-1144, doi:10.1177/0333102410363490 (2010).
- 56 Schneckloth, R., Page, I. H., Del Greco, F. & Corcoran, A. C. Effects of serotonin antagonists in normal subjects and patients with carcinoid tumors. *Circulation* **16**, 523-532, doi:10.1161/01.cir.16.4.523 (1957).
- 57 Faillace, L. A., Vourlekis, A. & Szara, S. Clinical evaluation of some hallucinogenic tryptamine derivatives. *J Nerv Ment Dis* **145**, 306-313 (1967).
- 58 Glennon, R. A., Young, R., Jacyno, J. M., Slusher, M. & Rosecrans, J. A. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. *Eur J Pharmacol* **86**, 453-459 (1983).
- 59 Violin, J. D., Crombie, A. L., Soergel, D. G. & Lark, M. W. Biased ligands at G-protein-coupled receptors: promise and progress. *Trends Pharmacol Sci* **35**, 308-316, doi:10.1016/j.tips.2014.04.007 (2014).

- 60 Boursier, M. E., Levin, S., Hurst, R. & Ohana, R. F. Equilibrium and Kinetic Measurements of Ligand Binding to HiBiT-tagged GPCRs on the Surface of Living Cells. *Bio Protoc* **10**, e3861, doi:10.21769/BioProtoc.3861 (2020).
- 61 Boursier, M. E. *et al.* The luminescent HiBiT peptide enables selective quantitation of G protein-coupled receptor ligand engagement and internalization in living cells. *The Journal of biological chemistry* **295**, 5124-5135, doi:10.1074/jbc.RA119.011952 (2020).
- 62 Gray, J. A. & Roth, B. L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. *Brain Res Bull* **56**, 441-451, doi:10.1016/s0361-9230(01)00623-2 (2001).
- 63 Van Oekelen, D., Luyten, W. H. & Leysen, J. E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. *Life Sci* **72**, 2429-2449, doi:10.1016/s0024-3205(03)00141-3 (2003).
- 64 Rinaldi-Carmona, M. *et al.* Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain. *Mol Pharmacol* **43**, 84-89 (1993).
- 65 Halberstadt, A. L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. *Behav Brain Res* **277**, 99-120, doi:10.1016/j.bbr.2014.07.016 (2015).
- 66 Carlsson, M. L. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis. *J Neural Transm Gen Sect* **100**, 225-237, doi:10.1007/BF01276460 (1995).
- 67 de la Fuente Revenga, M. *et al.* Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice. *ACS Chem Neurosci* **13**, 2436-2448, doi:10.1021/acscchemneuro.2c00170 (2022).
- 68 Schmid, C. L. & Bohn, L. M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. *J Neurosci* **30**, 13513-13524, doi:10.1523/JNEUROSCI.1665-10.2010 (2010).
- 69 Cunningham, M. J. *et al.* Pharmacological Mechanism of the Non-hallucinogenic 5-HT(2A) Agonist Ariadne and Analogs. *ACS Chem Neurosci*, doi:10.1021/acscchemneuro.2c00597 (2022).
- 70 Vickers, S. P. *et al.* Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. *Pharmacol Biochem Behav* **69**, 643-652 (2001).
- 71 Dursun, S. M. & Handley, S. L. Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. *Psychopharmacology (Berl)* **128**, 198-205 (1996).
- 72 Cussac, D. *et al.* Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. *Eur J Pharmacol* **594**, 32-38, doi:10.1016/j.ejphar.2008.07.040 (2008).
- 73 van Niel, J. C., Schneider, J. & Tzschentke, T. M. Efficacy of Full micro-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence. *Drug Res (Stuttg)* **66**, 562-570, doi:10.1055/s-0042-109393 (2016).
- 74 Zhou, X. E. *et al.* Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors. *Cell* **170**, 457-469 e413, doi:10.1016/j.cell.2017.07.002 (2017).
- 75 Peng, Y. *et al.* 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. *Cell* **172**, 719-730 e714, doi:10.1016/j.cell.2018.01.001 (2018).
- 76 Xu, Z. *et al.* Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism. *Nature chemical biology* **18**, 281-288, doi:10.1038/s41589-021-00930-3 (2022).
- 77 Cao, C. *et al.* Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. *Neuron* **110**, 3154-3167 e3157, doi:10.1016/j.neuron.2022.08.006 (2022).
- 78 Besnard, J. *et al.* Automated design of ligands to polypharmacological profiles. *Nature* **492**, 215-220, doi:10.1038/nature11691 (2012).
- 79 Olsen, R. H. J. *et al.* TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. *Nature chemical biology* **16**, 841-849, doi:10.1038/s41589-020-0535-8 (2020).
- 80 Klein, A. K. *et al.* Investigation of the Structure-Activity Relationships of Psilocybin Analogues. *ACS Pharmacol Transl Sci* **4**, 533-542, doi:10.1021/acspstsci.0c00176 (2021).

- 81 Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A. & Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. *Journal of medicinal chemistry* **49**, 534-553, doi:10.1021/jm050540c (2006).
- 82 Nikolova, V., Cheshmedzhieva, D., Ilieva, S. & Galabov, B. Atomic Charges in Describing Properties of Aromatic Molecules. *J Org Chem* **84**, 1908-1915, doi:10.1021/acs.joc.8b02908 (2019).
- 83 Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. *Nucleic Acids Res* **40**, D370-376, doi:10.1093/nar/gkr703 (2012).
- 84 Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* **27**, 221-234, doi:10.1007/s10822-013-9644-8 (2013).
- 85 Jacobson, M. P. *et al.* A hierarchical approach to all-atom protein loop prediction. *Proteins* **55**, 351-367, doi:10.1002/prot.10613 (2004).
- 86 Greenwood, J. R., Calkins, D., Sullivan, A. P. & Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. *J Comput Aided Mol Des* **24**, 591-604, doi:10.1007/s10822-010-9349-1 (2010).
- 87 Schmid, N. *et al.* Definition and testing of the GROMOS force-field versions 54A7 and 54B7. *Eur Biophys J* **40**, 843-856, doi:10.1007/s00249-011-0700-9 (2011).
- 88 Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. *J Mol Graph* **14**, 33-38, 27-38, doi:10.1016/0263-7855(96)00018-5 (1996).
- 89 Halberstadt, A. L. & Geyer, M. A. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. *Psychopharmacology (Berl)* **227**, 727-739, doi:10.1007/s00213-013-3006-z (2013).
- 90 Halberstadt, A. L. & Geyer, M. A. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. *Neuropharmacology* **77**, 200-207, doi:10.1016/j.neuropharm.2013.08.025 (2014).
- 91 Halberstadt, A. L. Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. *Sci Rep* **10**, 8344, doi:10.1038/s41598-020-65264-x (2020).
- 92 Tanaka, S., Young, J. W., Halberstadt, A. L., Masten, V. L. & Geyer, M. A. Four factors underlying mouse behavior in an open field. *Behav Brain Res* **233**, 55-61, doi:10.1016/j.bbr.2012.04.045 (2012).

ACKNOWLEDGEMENTS

This work was supported by Medical College of Wisconsin Research Affairs Counsel Pilot grant (JDM), National Institutes of Health General Medical Sciences grant (NIGMS R35GM133421 to JDM) and National Institutes of Health Drug Abuse (NIDA R01DA041336 to ALH), as well as by the Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center. We thank technical assistance from Lisa McNally.

AUTHOR CONTRIBUTIONS

The study was conceived by JW, ALH, and JDM. Compounds were synthesized and analytically characterized by JW, HM, JG, and TF. BRET, calcium flux, binding, mutagenesis, kinetics, and internalization experiments were performed by ABC, MMC, JKL, HAB, EMB, JJH, and EIA under the supervision of JDM. *In vivo* behavioral experiments were performed by ALH, RK, AKK, and BC. RZ and AJH conducted the docking and molecular dynamics simulations and helped write docking and MD sections. JW, ALH and JDM drafted and edited the original manuscript. All authors reviewed the manuscript.

COMPETING INTERESTS

JW, ALH, and JDM have submitted a patent application for the compounds in this study. AKK is currently an employee of Gilgamesh Pharmaceuticals.

FIGURE CAPTIONS

Figure 1. Psychedelics exhibit similar Gq and β -arrestin2 activity at 5-HT_{2A}R

Schematic of 5-HT_{2A} receptor G protein dissociation **(A)** and β -arrestin recruitment **(B)** to determine signaling preferences. **(C)** Determination of 5-HT_{2A} receptor G protein-wide and β -arrestin1/2 transducer preferences as estimated by magnitude net BRET for each transducer as stimulated by 5-HT. Data represent the mean and SEM from three independent experiments, which were performed at 37°C with 60 minute compound incubations. **(D-K)** Comparison of 5-HT_{2A} receptor Gq dissociation (red) and β -arrestin2 recruitment (blue) for 5-HT **(D)** and several classes of psychedelics: **(E)** Psilocin, **(F)** DMT, **(G)** 5-MeO-DMT, **(H)** 2C-I, **(I)** DOI, **(J)** 25I-NBOMe, **(K)** LSD. Data represent the mean and SEM from three independent experiments, which were performed at 37°C with 60 minute compound incubations. **(L)** Heat map of Gq dissociation and β -arrestin2 recruitment kinetics displayed as log (E_{MAX}/EC_{50}) for the psychedelics tested. Data represent the mean and SEM from three independent experiments, which were performed at 37°C at the indicated compound incubation time points.

Figure 2. Rational design of a 5-HT_{2A}-selective agonist template

(A) N-Benzoylation of 25N (1) to 25N-NB (2) leads to reduced 5-HT_{2B} receptor efficacy, as measured by Gq dissociation by BRET. Data represent the mean and SEM from three independent experiments performed at 37°C with 60 minute compound incubation. **(B)** Role of N-benzyl ring electrostatics in 5-HT_{2A} receptor potency leading to development of 25N-NB-2-OH-3-Me (18) using QSAR. Correlation between 5-HT_{2A} receptor pK_i and Hammett constant values (Pearson's $R = -0.9078$, $R^2 = 0.8241$, $p < 0.0001$, $N = 16$). **(C)** The relationship between steric bulk and 5-HT_{2A/2C} receptor selectivity is shown for the halogen series, leading to the identification of the 5-HT_{2A} receptor-selective agonist 25N-NBI (10) (*left*). Also shown is a 5-HT_{2A/2C} receptor selectivity heatmap comparing the 25N halogen series to 25CN-NBOH (*right*). **(D)** Comparison of 5-HT_{2A} receptor (green) 5-HT_{2B} receptor (red) and 5-HT_{2C} receptor (purple) Gq dissociation activities for 25N-NBI (10) (*left*) and 25CN-NBOH (*right*). Data represent mean and SEM from three independent experiments, which were performed at 37°C with 60 minute compound incubation **(E)** 5-HT_{2A} receptor Gq dissociation and β -arrestin2 BRET concentration response curves for 25N-NBOH (3, *top*) and 25N-NB-2-OH-3-Me (18, *bottom*) showing addition of a 3-methyl group leads to reduced Gq efficacy. **(F)** 25N-NBI (10) induced fit docking (IFD) with orthosteric site residue side chains displayed. The window shows a zoom-in view illustrating key ligand-residue interactions within the orthosteric site and illustrating the close proximity of the 2'- and 3'-positions to TM6 and TM7, which are known to influence ligand bias. **(G)** Summary of structure-activity relationships (SAR) for the 25N series encompassing key effects on electrostatics, 5-HT_{2A} receptor selectivity, and reduced Gq E_{MAX} .

Figure 3. Structure-based design of β -arrestin-biased 5-HT_{2A} agonists

(A) Effect of the larger N-substituted 25N analogs 25N-N1-Nap (16) and 25N-NBPh (17) on 5-HT_{2A} receptor Gq dissociation (red) and β -arrestin2 (blue) recruitment. Data represent the mean and SEM from three independent experiments performed at 37°C with 60 minute compound incubation. **(B)** Outward pivot of TM6 for 25CN-NBOH and 25N-N1-Nap (16) MD simulations relative to the inactive 5-HT_{2A} receptor structure with final frame shown as representative. Note the intermediate TM6 tilt angle with 25N-N1-Nap (16) relative to that of 25CN-NBOH. **(C)** Change in W366^{6.48} toggle switch χ^2 angle. χ^2 angle given is the absolute difference in peak angle relative to the inactive state. Final frame shown as representative. **(D)** Distribution and time dependence W366^{6.48} χ^2 angle of 25CN-NBOH (yellow) and 25N-N1-Nap (16) (orange) simulations. **(E)** Effect of 5-HT_{2A} receptor W366^{6.48}Y mutation on 25N-NBOMe (4), 25N-NBPh (17), and 25N-N1-Nap (16) Gq dissociation (red) versus β -arrestin2 (blue) recruitment activities. Data represent the mean and SEM from three independent experiments performed at 37°C with 60 minute compound incubation.

Figure 4. β -Arrestin-biased 5-HT_{2A} agonists lack psychedelic potential

(A) Effect of 25N-NBOMe (4) on the head-twitch response (HTR). * $p < 0.05$, significant difference vs. vehicle control (Dunnett's T3 test). **(B)** Effect of 25N-N1-Nap (16) on the HTR. **(C)** Effect of 25N-NBPh (17) on the HTR. **(D)** Effect of 25N-NB-2-OH-3-Me (18) on the HTR. **(E)** Illustration showing the procedures used to confirm that compounds tested in panels F–H are brain penetrant and capable of engaging 5-HT_{2A} receptors in the CNS of mice. Mice were pretreated with vehicle or drug, ($\pm$)-DOI (1 mg/kg IP) was injected 10 minutes

later, and then HTR activity was assessed for 20 minutes. **(F)** Pretreatment with 25N-N1-Nap (16) blocks the HTR induced by ($\pm$)-DOI ($F_{3,16} = 68.43, p < 0.0001$). **(G)** Pretreatment with 25N-NBPh (17) blocks the HTR induced by ($\pm$)-DOI ($W_{3,14.64} = 144.6, p < 0.0001$). **(H)** Pretreatment with 25N-NB-2-OH-3-Me (18) blocks the HTR induced by ($\pm$)-DOI ($F_{3,16} = 18.39, p < 0.0001$). $*p < 0.05$, $***p < 0.001$, $****p < 0.0001$, significant difference between groups (Tukey's test or Dunnett's T3 test). HTR counts from individual male C57BL/6J mice as well as group means are shown. Drug doses are presented as mg/kg. **(I)** 5-HT_{2A} receptor Gq-mediated calcium flux activity comparing 5-HT (open circles) antagonist activity for 25N-N1-Nap (16) (red), 25N-NB-2-OH-3-Me (18) to M100,907 (black circles). BRET data represent the mean and SEM from three independent experiments.

Figure 5. 5-HT_{2A}-Gq signaling predicts psychedelic potential

(A) Scatter plot showing the relationship between 5-HT_{2A} receptor Gq efficacy (E_{MAX} values) and head-twitch response (HTR) magnitude (maximum counts per minute induced by the compound) for 14 members of the 25N series. Spearman's rank correlation coefficient R_s is shown. The regression line generated by fitting the data using non-linear regression is included as a visual aid. **(B)** Scatter plot showing the relationship between 5-HT_{2A} receptor β -arrestin2 recruitment efficacy (E_{MAX} values) and HTR magnitude for 14 members of the 25N series. **(C)** Scatter plot showing the relationship between 5-HT_{2A} receptor Gq efficacy (E_{MAX} values) and HTR magnitude for 24 phenethylamine psychedelics. To illustrate the non-linear nature of the relationship, the regression line generated by fitting the data using non-linear regression is shown. **(D)** Scatter plot showing the relationship between 5-HT_{2A} receptor β -arrestin2 recruitment efficacy (E_{MAX} values) and HTR magnitude for 24 phenethylamine psychedelics. **(E-K)** Activity in the HTR assay can be predicted based on 5-HT_{2A} receptor Gq efficacy. As predicted, 25O-NBOMe (32) ($F_{5,26} = 37.01, p < 0.0001$), 2C2-NBOMe (31) ($W_{6,12.67} = 96.28, p < 0.0001$), and 25O-NBcP (33) ($F_{5,25} = 20.57, p < 0.0001$) induced head twitches, whereas 25O-NBPh-10'-OH (35) ($F_{4,27} = 2.58, p = 0.0601$), 25O-NB-3-I (34) ($F_{5,25} = 0.26, p = 0.9288$), and 25D-N1-Nap (26) ($F_{3,20} = 0.37, p = 0.7748$) did not induce head twitches. **(L)** Pretreatment with the Gq/11 inhibitor YM-254890 blocks the HTR induced by R(-)-DOI ($F_{3,12} = 8.69, p = 0.0025$). Mice were treated ICV with YM-254890 or vehicle and then all of the animals received R(-)-DOI (1 mg/kg IP) 15 minutes later. **(M)** Pretreatment with the phospholipase C (PLC) inhibitor edelfosine blocks the HTR induced by R(-)-DOI ($F_{2,16} = 11.34, p = 0.0009$) and 25N-NBOMe (4) ($F_{2,16} = 6.40, p = 0.0091$). Mice received three consecutive injections of vehicle or the indicated dose of edelfosine at 20-minute intervals and then a HTR-inducing drug was administered 10 minutes after the third injection. HTR counts from individual male C57BL/6J mice as well as group means are shown. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, $****p < 0.0001$, significant difference vs. vehicle control (Tukey's test or Dunnett's T3 test).

Figure 6. Non-psychedelics do not achieve 5-HT_{2A} Gq-signaling efficacy threshold


(A) Effect of (+)-lysergic acid diethylamide (LSD), psilocin, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), N,N-diethyltryptamine (DET), lisuride, (+)-2-bromolysergic acid diethylamide (2-Br-LSD), 6-methoxy-N,N-dimethyltryptamine (6-MeO-DMT), and 6-fluoro-N,N-diethyltryptamine (6-F-DET) on 5-HT_{2A} receptor Gq dissociation (red) and β -arrestin2 (blue) recruitment. The BRET data for LSD, psilocin, and 5-MeO-DMT are from Fig. 1; the data for 2-Br-LSD were published previously¹¹. Data represent the mean and SEM from three independent experiments. **(B)** Effect of LSD, psilocin, 5-MeO-DMT ($F_{4,26} = 3.09, p = 0.0331$), DET, lisuride, 2-Br-LSD, 6-MeO-DMT ($F_{5,26} = 4.19, p = 0.0063$), and 6-F-DET ($F_{4,23} = 13.49, p < 0.0001$) on the head-twitch response (HTR) in mice. The HTR data for LSD, DET, psilocin, lisuride, and 2-Br-LSD were re-analyzed from published experiments^{9,11,80,89}. HTR counts from individual male C57BL/6J mice as well as group means are shown. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, $****p < 0.0001$, significant difference between groups (Tukey's test). **(C)** Scatter plot and linear regression showing the correlation between 5-HT_{2A} receptor Gq efficacy (E_{MAX} values) and HTR magnitude (maximum counts per minute induced by each drug). Pearson's correlation coefficient R is shown.

Figure 7. In vitro and in vivo effects of β -arrestin-biased 5-HT_{2A} agonists


(A) Scheme of NanoBit Internalization Assay for 5-HT_{2A} receptor measuring loss of surface expression with the membrane impermeable LgBit. **(B)** 5-HT_{2A} receptor internalization concentration response as calculated as percent basal surface expression and normalized to 0% of max 5-HT response. Data represent mean and SEM from 3 independent experiments with 5-HT (black), DOI (blue), pimavanserin (grey), 25N-NBOMe (4) (green), 25N-N1-Nap (16) (red) and 25N-NBPh (17) (purple). **(C)** Cartoon showing the procedures used to induce tolerance in the head-twitch response (HTR) assay. Mice were injected with vehicle or drug once daily for 5 consecutive days and then challenged with ($\pm$)-DOI (1 mg/kg/day IP) 24 hours after the last injection. **(D)** Repeated daily administration of ($\pm$)-DOI and 25N-N1-Nap (16), but not pimavanserin, induces a tolerance to

the HTR induced by DOI. One set of mice ($n=6-7/\text{group}$) was treated with vehicle, 25N-N1-Nap (16) (20 mg/kg/day SC), or ($\pm$)-DOI (10 mg/kg/day SC) once daily for 5 consecutive days. A second set of mice ($n=6/\text{group}$) was treated with vehicle or pimavanserin (1 mg/kg/day SC) once daily for 5 consecutive days. HTR counts are expressed as a percentage of the response in the respective vehicle control group; data from individual male C57BL/6J mice as well as group means are shown. $**p<0.01$, $***p<0.001$, significant difference between groups (Tukey's test). **(E)** Pretreatment with the 5-HT_{2A} receptor antagonist pimavanserin blocks the HTR induced by ($\pm$)-DOI ($F_{3,16} = 8.19$, $p=0.0016$). HTR counts from individual mice as well as group means are shown. $**p<0.01$, significant difference between groups (Tukey's test). **(F)** Pretreatment with 25N-N1-Nap (16) attenuates phencyclidine (PCP)-induced locomotor hyperactivity (25N-N1-Nap (16) $\times$ PCP: $F_{1,20} = 7.09$, $p=0.015$; 25N-N1-Nap (16) $\times$ PCP $\times$ time: $F_{2,40} = 11.03$, $p=0.0002$). Locomotor activity was measured as distance traveled in cm. $*p<0.05$, significant difference vs. vehicle control; $^{\#}p<0.05$, significant difference vs. PCP alone (Tukey's test). **(G)** M100907 pretreatment attenuates PCP-induced locomotor hyperactivity (M100907 $\times$ PCP: $F_{1,20} = 7.41$, $p=0.0131$). $*p<0.05$, significant difference vs. vehicle control; $^{\#}p<0.05$, significant difference vs. PCP alone (Tukey's test). Distance traveled in male C57BL/6J mice are presented as group means $\pm$ SEM. Drug doses are presented as mg/kg.


A




B




C




D




E




F




G




H




I



J





K








L


	5 min	30 min	60 min	120 min	300 min	
5-HT	8.31	8.16	8.04	8.43	8.48	Gq Dissociation
	8.03	7.78	7.82	7.83	7.81	β-Arr2 Recruitment
Psilocin	7.58	7.50	7.54	7.58	7.58	Gq Dissociation
	7.06	7.06	6.88	7.07	7.14	β-Arr2 Recruitment
DMT	6.64	6.58	7.07	6.90	7.00	Gq Dissociation
	6.63	6.55	6.57	6.88	6.72	β-Arr2 Recruitment
5-MeO-DMT	7.35	7.75	7.66	7.54	7.60	Gq Dissociation
	7.61	7.61	7.35	7.71	7.73	β-Arr2 Recruitment
2C-I	8.66	8.54	8.70	8.75	8.77	Gq Dissociation
	8.44	7.94	8.08	7.73	7.85	β-Arr2 Recruitment
(±)-DOI	8.83	8.88	9.00	8.90	8.82	Gq Dissociation
	8.44	8.66	8.50	8.59	8.44	β-Arr2 Recruitment
25I-NBOMe	8.95	9.33	9.49	9.81	9.98	Gq Dissociation
	9.08	9.34	9.47	9.50	9.43	β-Arr2 Recruitment
LSD	8.62	9.17	9.17	9.86	10.00	Gq Dissociation
	8.20	8.62	9.27	9.30	9.53	β-Arr2 Recruitment






























A**Psychedelic****Non-psychedelic****B****Psychedelic****Non-psychedelic****C**

A


bioRxiv preprint doi: <https://doi.org/10.1101/2023.07.29.551196>; this version posted July 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.




B




C




D



E



F



G

